Investigation of Sox9 ablation on neuroplasticity and recovery after ischemic stroke by Bass, Bethany Robin Lenore
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
8-29-2014 12:00 AM 
Investigation of Sox9 ablation on neuroplasticity and recovery 
after ischemic stroke 
Bethany Robin Lenore Bass 
The University of Western Ontario 
Supervisor 
Dr. Arthur Brown 
The University of Western Ontario 
Graduate Program in Anatomy and Cell Biology 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Bethany Robin Lenore Bass 2014 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Neurosciences Commons 
Recommended Citation 
Bass, Bethany Robin Lenore, "Investigation of Sox9 ablation on neuroplasticity and recovery after 
ischemic stroke" (2014). Electronic Thesis and Dissertation Repository. 2338. 
https://ir.lib.uwo.ca/etd/2338 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
i 
 
INVESTIGATION OF SOX9 ABLATION ON NEUROPLASTICITY AND 
RECOVERY AFTER ISCHEMIC STROKE 
 
Thesis format: Monograph 
 
 
by 
 
 
 
Bethany Bass  
 
 
 
 
Graduate Program in Anatomy and Cell Biology 
 
 
 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of  
Master of Science 
 
 
 
 
The School of Graduate and Postdoctoral Studies 
The University of Western Ontario 
London, Ontario, Canada 
 
 
 
 
© Bethany Bass 2014 
ii 
 
Abstract 
 Neuroplasticity is a key factor in post-stroke functional recovery.  A chief 
inhibitor of post-stroke neuroplasticity is the expression of chondroitin sulfate 
proteoglycans (CSPGs). Recent research has shown that the transcription factor SOX9 is 
responsible for upregulating the expression of CSPGs in the injured central nervous 
system. Accordingly, CSPG levels are significantly lower in mice with the Sox9 gene 
conditionally knocked out. The purpose of this study was to determine how Sox9 ablation 
affects neuroplasticity and recovery after stroke.  Behavioural test results revealed that 
Sox9 KO mice exhibited significantly improved functional recovery after stroke 
compared to controls.  This correlated with increased contralesional corticofugal 
plasticity in the Sox9 KO animals, as highlighted by tract tracing studies. An increase in 
one type of glutamatergic input marker (VGLUT1) was observed at the deafferented red 
nucleus of the Sox9 KO mice, but not at the denervated the cervical spinal cord ventral 
horn.  Further investigation into the effects of Sox9 ablation on post-stroke 
neuroplasticity would be beneficial to determine the potential of Sox9 as a therapeutic 
target.  
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Chapter 1: 
 
Introduction 
1.1   Stroke prevalence 
 A stroke is defined as a sudden loss of brain function due to an interruption in 
blood supply to the brain. Stroke is a leading cause of death worldwide, second only to 
ischemic heart disease (WHO 2013).  Despite the fact that many risk factors for stroke 
are modifiable (hypertension, activity level, weight etc.), stroke is the third leading cause 
of death, and the leading cause of long-term disability in adults in Canada (CSN 2012; 
StatsCan 2012).   There are three main types of stroke: ischemic stroke (lack of blood 
flow), intracerebral hemorrhage (bleeding within the brain), and atraumatic subarachnoid 
hemorrhage (rupture of an aneurysm at the base of the brain).  All three types of stroke 
can lead to loss of function, but they differ in the subsets of people they usually affect, as 
well as their causes, treatments, and outcomes.   It is a debilitating condition that not only 
puts significant strain on the approximately 300,000 individuals living with the effects of 
a stroke in Canada (as well as their family members), but which also burdens the 
economy (PHAC 2009).  Stroke costs approximately $3.6 billion per year in Canada in 
health care expenditures, as well as lost economic output and productivity due to long-
term disability and premature mortality (PHAC 2009; PHAC 2011).   While it is 
imperative to continue to place emphasis on stroke prevention, such high rates of 
disability and death due to stroke indicate that new approaches to treatment must be 
investigated as well.  
 
1.2  Risk factors and causes of ischemic stroke  
 Ischemic stroke (which is modeled in this study) is described as the blockage of a 
vessel that supplies blood to the brain.  This results in the deprivation of vital glucose and 
oxygen to the most metabolically active organ in the body.  It is the most common type of 
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stroke and accounts for about 80% of all cases in Canada, while the rest are hemorrhagic 
(CSN 2011; Lu 2011).  There are both potentially modifiable and non-controllable risk 
factors for ischemic stroke.  The most significant risk factor for stroke is a person’s age, 
which is non-modifiable.  After 55 years of age, the risk of stroke doubles every decade 
for both men and women (Sacco, Benjamin et al. 1997; Gorelick and Ruland 2010).  
More women than men tend to die of stroke each year despite the rate of stroke being 
1.25 times higher in men.  This can be attributed to the fact that women tend to live 
longer than men do (Sacco, Benjamin et al. 1997).  Heredity also plays a role in a 
person's risk for ischemic stroke, as increased incidence of stroke among families has 
been observed.  Reasons for this may include heredity of genetic factors that increase 
susceptibility for risk factors of stroke itself, or family members' exposure to common 
predisposing environmental and lifestyle factors.  In the same way, some ethnicities are 
known to experience higher rates of incidence and mortality with ischemic stroke. For 
example, people of African-American descent are more than twice as likely to die of 
ischemic stroke than Caucasian people; however, this too may also be due to a 
combination of inherited factors other than race, and environmental factors (Sacco, 
Benjamin et al. 1997). 
 Hypertension is considered the most important modifiable risk factor for ischemic 
stroke. A number of studies have shown that treating hypertension in patients 
significantly lowers the incidence of stroke among them; data combined from seventeen 
treatment trials of hypertension worldwide show a 38% reduction in stroke and a 40% 
reduction in fatal stroke (Sacco, Benjamin et al. 1997).  Certain cardiac diseases are also 
known to increase the incidence of stroke, with atrial fibrillation (irregular heart rhythm) 
being the most notable, which occurs in almost half of all patients who experience a 
cardioembolic stroke.  Cigarette smoking is known to double a person's risk of suffering 
an ischemic stroke.  Other modifiable risk factors include living a sedentary lifestyle, 
obesity, diabetes, and hypercholesterolemia, all of which increase a patient's 
susceptibility for atherosclerosis (Sacco, Benjamin et al. 1997; Lu 2011).  The occurrence 
of transient ischemic attacks can also serve as a warning sign for a future ischemic stroke 
(Lu 2011). 
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 Whether they are modifiable or not, these risk factors can contribute to the 
primary causes of ischemic stroke: embolism, or thrombosis.  Systemic hypoperfusion 
can also cause ischemia in the brain, but is less common, and results from decreased 
cardiac output or hypovolemia (Rovira, Grive et al. 2005).  The model used in this 
research project aims to emulate the majority of ischemic strokes, caused by embolism or 
thrombosis.  About twenty-five percent of ischemic strokes are due to embolism, which 
occurs when a cerebral artery is blocked by a clot or debris that travels from a distant site 
in the body (e.g. cardioembolic stroke occurs when a clot from the heart dislodges and 
travels to the brain).  Emboli can come from the heart (as mentioned), arteries, and veins, 
and often occur with medical conditions that lead to abnormally increased tendencies of 
blood clotting (e.g. antiphospholipid syndrome, deficiencies of anti-clotting factors, 
supplemental estrogen use, etc.) (Sacco, Benjamin et al. 1997).  Emboli can develop on 
diseased, damaged or prosthetic valves, and atheroslerotic emboli that cause ischemic 
stroke commonly come from the aortic arch or extracranial arteries.  About fifty percent 
of ischemic strokes are due to thrombosis, in which a thrombus (blood clot), occludes a 
cerebral artery (Lu 2011).  Large-vessel thrombotic strokes are the most common, and are 
often due to long-term atherosclerosis followed by a rapid blood clot formation.  Less 
commonly, thrombotic strokes in small arteries occur, leading to lacunar infarctions 
(Zorowitz R 2004).   
 
1.3  Treatments and outcomes of ischemic stroke 
 Current treatments for ischemic stroke range from acute (within a few hours of 
stroke onset) to long-term rehabilitation.  Currently, the only FDA and Health Canada-
approved drug for ischemic stroke treatment is tPA, or recombinant human tissue 
plasminogen activator, which is considered the gold standard of acute treatment.  Tissue 
plasminogen activator is the major enzyme involved in the breakdown of blood clots, 
which catalyzes the conversion of plasminogen to plasmin and is most commonly 
delivered intravenously.  A tPA clinical study by the National Institute of Neurological 
Disorders and Stroke found that, although there was an increased risk for intracerebral 
hemorrhage to occur with the delivery of tPA, patients who received it within the correct 
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window of time experienced a 12% increase in excellent functional outcome and a 4% 
risk reduction in mortality (NINDS 1995).  Unfortunately, only a small percent of 
ischemic stroke patients (estimated at 3%) receive this drug due to it's very narrow time 
window for safe administration, which is 3-4.5 hours post-onset of stroke (Lansberg, 
Bluhmki et al. 2009; Armstead WM 2010).  People who experience a stroke may not 
recognize their symptoms as being indicative of a medical emergency (e.g. unilateral 
numbness or weakness of the face, arm or leg, visual problems, difficulty speaking or 
understanding speech, dizziness, etc.) and may delay seeking medical attention (Moser, 
Kimble et al. 2006; Lu 2011).  Even upon arrival at a hospital, it is necessary to perform a 
non-contrast head CT to determine whether symptoms are due to an ischemic or 
hemorrhagic stroke, or an altogether different neuropathology (e.g. tumour, abscess) (Lu 
2011). After this initial 3 - 4.5 hour time point, IV tPA treatment to breakdown blood 
clots is considered ineffective in reducing the amount of infarcted tissue, and increases 
the risk for intracerebral hemorrhage to occur (NINDS 1995).    
 Intra-arterial thrombolytic delivery is another option for treatment, and stretches 
the treatment time window to about six hours after the onset of ischemic stroke.  This 
method involves inserting a microcatheter into the vasculature and delivering 
thrombolytics locally to the site of the occlusion.  This is usually a 1 to 2 hour process 
that involves simultaneous angiographic imaging.  As such, intra-arterial thrombolytic 
treatment is a much more complicated process than IV tPA therapy, and requires more 
medical professionals and equipment on hand than the latter; however, it boasts overall 
superior recanalization rates of major cerebrovascular occlusions compared to tPA, most 
significantly with large vessel occlusions.  There are current clinical trials investigating 
the combinatorial treatment of tPA and intra-arterial thrombolytic delivery (Grigoryan 
and Qureshi 2010). 
 For a number of reasons, IV delivery of tPA may fail, or a patient may simply be 
ineligible for thrombolytic therapy because the risk for intracerebral hemorrhage or other 
complications would be too high.  In such cases, there are endovascular surgical 
treatment options.  An endovascular thrombectomy involves threading a flexible wire 
with helical loops into the thrombus and retrieving it.   Endovascular thromboaspiration is 
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another clot extraction approach that combines aspiration and debulking of the thrombus 
in an attempt to reduce or eliminate clotting.  Finally, angioplasty with stent placement is 
another endovascular option that is still being assessed.  Each treatment approach comes 
with a unique set of procedural complication risks, such as vessel rupture and distal 
embolization.  Many factors must go into consideration when choosing the best option for 
each patient (Grigoryan and Qureshi 2010).  
 Time is very much so of the essence when a stroke occurs. Unfortunately, even 
receiving emergency medical care may not be enough to prevent ischemic brain damage 
from occurring, which can lead to disability and even death.  In a study outlined by the 
Canadian Stroke Network (a review of hospital records across Canada between April 1, 
2008 to March 31, 2009),  the in-hospital mortality rate for patients admitted for ischemic 
stroke was 14% after 30 days in the hospital (CSN 2011).  The mortality rates for stoke 
have declined over the past few decades; however, this means that survivors are 
increasingly likely to live with functional and cognitive impairments and disabilities.  
The disabling aspects of stroke seem to be feared more than possible fatality, as surviving 
stroke victims have stated that they believe that severe disability would be a worse 
outcome than death (PHAC 2009).  Unfortunately, more than half of all long-term stroke 
survivors (>6 months) acquire some sort of disability (mild to severe), which contributes 
to lower quality of life (Sacco, Benjamin et al. 1997; Clarke, Marshall et al. 2002; PHAC 
2009). 
 Beyond drug and surgical therapies for ischemic stroke, rehabilitation has proved 
to be beneficial for functional recovery.   More specifically, physiotherapy is one of the 
most important disciplines in interdisciplinary stroke rehabilitation.  Physiotherapy 
usually starts within the first few days after the onset of stroke, and often continues into 
the chronic phase.  The main goal of post-stroke physiotherapy is to re-establish the 
patient's ability to independently perform basic activities of daily living, such as feeding, 
bathing, dressing, and being mobile (Veerbeek, van Wegen et al. 2014).  A number of 
studies and meta-analyses emphasize that higher intensities and quantities of physical 
therapy practices after stroke lead to better results in terms of functional recovery 
(Veerbeek, van Wegen et al. 2014).   Although a particular method of physiotherapy has 
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yet to be determined to be superior to others, constraint-induced movement therapy has 
shown promising results.  This involves restraining the limb unaffected by the stroke and 
intensively using the affected limb (Johansson 2000).   
  Repetition is key to motor learning, and echoes the Hebbian learning rule that 
connections between neurons are strengthened when they are activated simultaneously 
(e.g. long term potentiation) (Veerbeek, van Wegen et al. 2014).  The main concept of 
post-stroke physiotherapy involves the use of exercise to induce activity-dependent 
modification of synaptic connections and reorganization of cortical areas (Johansson 
2000).   Unfortunately, certain factors in the post-stroke central nervous system work 
against this beneficial neuroplasticity.  Even with physiotherapy, it is estimated that only 
about half of all stroke survivors are able to perform all activities of daily living without 
relying on assistance from others in the long term (Veerbeek, van Wegen et al. 2014).  In 
summary, the drug-based, surgical, and rehabilitative therapies currently available to treat 
ischemic stroke patients do not add up to a cure, and different avenues of treatment need 
to be investigated.  
 
1.4 Ischemic injury to the central nervous system 
 Due to cortical neurons' high metabolic rates and energy substrate limitations 
(near-exclusive dependence on glucose), the effects of ischemia in the brain are 
immediate.  Within seconds under ischemic conditions, cortical activity local to the 
embolus or thrombus ceases as the neurons undergo an energy saving response.  
Transient plasma membrane hyperpolarization due to excessive K+ efflux occurs, 
followed by another dramatic rearrangement of ions across the plasma membrane.  This 
anoxic membrane depolarization causes the brain's normal cell-to cell signaling 
mechanisms to turn dangerous.  The resulting excessive release of neurotransmitters 
(glutamate in particular) is a major cause of ischemic neuronal death.  Massive glutamate 
release (initially by activated glutamatergic neurons, and later by reverse transport by 
astrocytes) involves the overstimulation of glutamate receptors.  This causes glutamate 
receptor ion channels to allow an excess of Ca+, Na+, and water into the cell, which is 
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particularly damaging for neurons.  Excess dopamine release can also contribute to 
neuronal death. This excitotoxicity encourages the spread of cellular depolarization, the 
depletion of energy stores, and the progression of cell injury cascades.  (Lee, Grabb et al. 
2000; Moskowitz, Lo et al. 2010). 
 This is where the concept of the ischemic core and penumbra comes into play.  
The ischemic core is defined as the area of the brain surrounding the embolus or 
thrombus where revival of tissue viability is not possible; the ischemic conditions have 
caused neuronal death.  The ischemic penumbra, on the other hand, is an area 
surrounding the core where mild to moderate hypoperfusion exists.  The neurons of this 
area cannot maintain their electrical activity to function normally; however, their ion 
channels are preserved so that the neurons can theoretically revert to normal functionality 
if blood flow is returned in a timely manner (generally within several hours of onset).  
Despite the obvious merits of post-ischemic reperfusion achieved by delivery of tPA or 
natural breakdown of the vessel blockage, it also brings its own brand of tissue damage 
risk in the form of reactive oxygen species (superoxide, hydroxyl, and nitric oxide 
radicals , etc.) and increased inflammation (Lee, Grabb et al. 2000).   
 Reactive oxygen species wreak havoc on the integrity of vital cellular components 
(such as DNA, lipids, proteins and enzymes, etc.), and further deplete cellular energy 
stores. The production of reactive oxygen species is also stimulated by other ischemic 
developments, such as Zn+ overload and glutamate toxicity (Lee, Grabb et al. 2000).  
Inflammation is another consequence of ischemia and reperfusion that can worsen tissue 
injury.  Cytokine production is increased, and the invasion of neutrophils ensues, 
followed by macrophages and monocytes.  This leads to microvascular obstruction as 
well as the production of toxic mediators by activated inflammatory and glial cells of the 
CNS.  All in all, the excitotoxicity, spreading depression, oxidative stress and 
inflammation within the ischemic tissue ultimately lead to cell death by apoptosis and 
necrosis.  Despite the creation of reactive oxygen species and increased inflammation, 
reperfusion is still considered ideal for revival of the penumbra if achieved in time (Lee, 
Grabb et al. 2000).  Functional loss experienced after a stroke depends on the extent of 
the ischemic damage, and the area in the brain in which it occurs.  
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1.5 Neuroplasticity in the post-stroke CNS, and how it relates to recovery 
 Neuronal death translates into loss of sensory and motor function, so central 
nervous system protection is a primary goal in stroke treatment.  Despite the level of the 
success that acute neuroprotective and rehabilitative treatment strategies have attained, 
there are still many limitations.  As such, another important area of research centers on 
understanding the endogenous restorative processes of the post-stroke central nervous 
system, so that we may develop ways to augment and facilitate these processes to 
improve recovery (Moskowitz, Lo et al. 2010).  Recovery after stroke is variable, but 
most sensory and motor recovery is generally observed within the first six months, (Wade 
and Hewer 1987; Bonita and Beaglehole 1988; Reding and Potes 1988; Murphy and 
Corbett 2009).  Similar patterns of spontaneous recovery (further augmented by 
rehabilitative therapy) can be seen in animal models, although the improvements seem to 
occur over a much shorter period of time than in humans (Murphy and Corbett 2009).  
Under normal circumstances, motor and sensory cortices are loosely organized into 
functional maps, which can undergo modifications and plastic changes by experience and 
use.  When stroke causes damage to these regions, it has been shown that the CNS 
undergoes a more pronounced "re-mapping" as recovery occurs (Murphy and Corbett 
2009).    
 Many correlations between recovery of function and post-stroke neuroplasticity in 
both the peri-infarct and more distant, unaffected parts of the CNS have been documented 
in the literature.  For example, a number of functional MRI studies have shown that peri-
infarct areas are highly active during recovery in both humans and animal models 
(Dijkhuizen, Singhal et al. 2003; Chopp, Zhang et al. 2007).   Other findings in human 
and animal models describe how partial recovery of hemiparesis (caused by a stroke 
involving the contralateral primary motor cortex) often involves either the activation of 
regions in the opposite undamaged hemisphere, or the activation of undamaged neurons 
ipsilateral to the stroke that are recruited to serve new functions (Pineiro, Pendlebury et 
al. 2001; Feydy, Carlier et al. 2002; Schaechter, Kraft et al. 2002; Small, Hlustik et al. 
2002; Dijkhuizen, Singhal et al. 2003; Fujii and Nakada 2003; Zemke, Heagerty et al. 
2003).  Indeed, to the extent that recovery occurs, neural function compromised by 
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ischemic injury seems to be reallocated to parallel pathways or to new alternate pathways 
by way of neuroplasticity: structural changes in surviving neurons leading to the creation 
of new neural connections, as well as altered electrical patterns in already existing 
connections (Lee, Kim et al. 2004; Murphy and Corbett 2009; Moskowitz, Lo et al. 
2010).  
 Neurogenesis is another process in the post-stroke CNS that may play a part in 
recovery.  After cerebral ischemia, newborn neurons originating from the subventricular 
and subgranular zones in adult mammalian brains (which normally migrate to the 
hippocampal and olfactory areas) travel towards damaged brain tissue (Arvidsson, Collin 
et al. 2002; Parent, Vexler et al. 2002).  However, many of these newborn cells only 
survive for a few days, and it is unclear if those that survive contribute significantly to 
post-stroke recovery.  Further research is needed to determine whether or not they 
develop normally, express neurotransmitters, or become part of functional neural 
networks (Moskowitz, Lo et al. 2010).  It is also fitting to discuss angiogenesis along 
with neurogenesis, as similar mediators and pathways are involved in both phenomena 
(Moskowitz, Lo et al. 2010).  New neuronal networks are only possible if suitable 
vascular networks can be established to support them.  As such, it is likely that CNS 
recovery after stroke relies on interdependent neurovascular re-modeling and plasticity 
that are guided by similar mediators and signals (Murphy and Corbett 2009; Snapyan, 
Lemasson et al. 2009).  
 In accordance with the theory that new cells may contribute to new circuits, stem 
cell therapy has been an appealing avenue of stroke research.  However, the improved 
functional outcome after brain ischemia often seen with stem or progenitor cell 
administration (e.g. intravenous administration of bone marrow stromal cells in rats) is 
most likely due to the production of trophic factors by these cells instead of 
differentiation into neuronal cells (Chen, Li et al. 2001; Murphy and Corbett 2009).  The 
trophic factors released enhance axonal sprouting, the elaboration of dendrites and spines, 
angiogenesis, and other processes that are important for neuroplasticity; so in extension, 
these studies further prove the benefits of a plastic CNS for post-stroke recovery, and that 
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it is important to keep all cell types in mind when examining recovery (neural, glial, and 
vascular) (Murphy and Corbett 2009).   
 Accordingly, in principle it would be beneficial to supply the damaged CNS with 
increased amounts of these trophic factors to augment recovery.  The administration of  
nerve growth factor (NGF), fibroblast growth factor (FGF), glial-derived neurotrophic 
factor (GDNF), and brain-derived neurotrophic factor (BDNF), for instance, to improve 
post-stroke recovery have been met with variable levels of success in animal models 
(Semkova and Krieglstein 1999).  Also of interest are proteins that encourage growth 
related processes, such as growth-associated protein 43 (GAP-43), myristoylated alanine-
rich C-kinase substrate (MARCKS), and brain-abundant signal protein 1 (BASP1) 
(Murphy and Corbett 2009).  Unfortunately, many of these growth-promoting molecules 
factors are relatively large, making transport past the blood-brain-barrier into the 
damaged CNS challenging.  Further research is needed to optimize trophic and/or 
pharmacologic factor delivery methods (e.g. using smaller peptides, or transnasal 
delivery to bypass blood-brain-barrier).  Another option would be to focus on compounds 
that can upregulate the production of endogenous trophic factors (Moskowitz, Lo et al. 
2010).  
 The benefits of neuroplasticity and its associations with recovery in the post-
stroke central nervous system have been cited thoroughly in the literature; hence, 
understanding what facilitates and limits this process could open the door to novel 
treatment approaches.  
 
1.6 Limitations to post-stroke central nervous system neuroplasticity 
 Opposite to trophic and growth-promoting factors are negative or inhibitory 
factors, which also play a big part in orchestrating neuroplasticity.  These include 
components of CNS myelin (e.g. Nogo A, MAG, etc.), inhibitory extracellular matrix 
(ECM) molecules that are often secreted by astrocytes, and receptors mediating growth 
cone collapse, which are normally developmentally-regulated (Lee, Kim et al. 2004).   
Perhaps the most salient of the inhibitory factors expressed in the injured CNS is a family 
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of ECM molecules called chondroitin sulfate proteoglycans (CSPGs) (Eddleston and 
Mucke 1993; Fawcett and Asher 1999; Silver and Miller 2004).  They have been shown 
to inhibit neurite outgrowth in many in intro and in vivo studies.  When a sprouting 
axon's growth cone comes in contact with CSPGs, protein tyrosine phosphate (PTP) 
receptors are activated, and the resulting signaling pathways lead to growth cone collapse 
(McKeon, Schreiber et al. 1991; Meiners, Powell et al. 1995; Davies, Fitch et al. 1997; 
Zuo, Neubauer et al. 1998). CSPGs are composed of one of a variety of core proteins 
covalently linked to chondroitin sulfate glycosaminoglycan chains, and are part of the 
normal CNS extracellular matrix.   
 In addition to serving both structural and functional roles in the generally loosely 
organized ECM throughout the CNS, CSPGs are also constituents of structures called 
peri-neuronal nets: highly condensed matrix arrangements surrounding the cell bodies 
and proximal dendrites of certain classes of neurons, which serve to stabilize synapses 
and limit synaptic plasticity.  The importance of peri-neuronal nets is seen especially in 
the "critical period" of postnatal CNS development.  This is a time when the CNS is 
particularly plastic, in which appropriate experience leads to the organization of proper 
neuronal networks.  A lack of appropriate experiences may cause the formation of 
incorrect neuronal connections (Wang and Fawcett 2012).  The high degree of plasticity 
and responsiveness to experience-based neuronal network formation in the critical period 
has been well studied in the visual system. The end of the postnatal critical period is 
marked by peri-neuronal net (PNN) deposition around neurons, which stabilizes 
established connections in the CNS and limits plastic changes due to future experiences 
(Wang and Fawcett 2012).  Along with the establishment of peri-neuronal nets, then end 
of critical period is also marked by a general upregulation of CSPGs in the CNS (Carulli, 
Pizzorusso et al. 2010).  After full CNS development, the disruption of PNNs can 
reactivate plasticity and allow for activity-dependent changes to more easily modify 
neuronal circuits (Wang and Fawcett 2012).  However, despite their essentiality to the 
proper development and function of the uninjured CNS, CSPGs can be detrimental to the 
injured CNS (Galtrey and Fawcett 2007).  
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  The expression of both axonal growth-promoting and growth-inhibiting genes is 
induced in specific waves and sequences in the post-stroke CNS (Carmichael, 
Archibeque et al. 2005).  The two main CNS regions that naturally experience tissue re-
organization (due to ischemic damage and the balance between these positive and 
negative factors) include a small area of cortex adjacent to the infarct area, as well as a 
broader region including peri-infarct cortex and more distant CNS areas.  As previously 
discussed, due to reduced blood flow, the area closely bordering the infarct core 
experiences oxidative DNA and protein damage, cell death, and reactive astrogliosis 
(increase of astrocyte number and activation) (Katsman, Zheng et al. 2003; Carmichael, 
Archibeque et al. 2005)  A consequence of astrocyte activation in this region is a massive 
increase in the production of axonal growth-inhibiting CSPGs.  Interestingly enough, this 
region simultaneously experiences increased expression of all of the growth-promoting 
genes soon after injury as well.  Despite this, axonal growth is limited in this area by the 
negative factors present, which may serve to decrease aberrant connectivity or simply 
interfere with the recovery process (Murphy and Corbett 2009).   
 The second area of interest (peri-infarct and more distant regions), however, 
experiences reduced CSPG expression (which translates to diminished peri-neuronal 
nets), as well as an increase in the expression of growth promoting genes.  This 
combination allows for increased axonal sprouting to occur in these areas, without 
detrimental astrocyte activation and cell death (Carmichael 2003; Carmichael, 
Archibeque et al. 2005).  Unfortunately, this decrease in CSPG expression is transient.  
Animal studies have shown that CSPG expression levels in these peri-infarct and remote 
CNS areas gradually increase over a month's time to return to normal levels, essentially 
closing the window of time for increased plasticity to occur (Carmichael, Archibeque et 
al. 2005).  Therefore, a possible strategy to improve recovery after stroke could be to 
lessen growth-inhibiting factors, thereby altering the CNS microenvironment to better 
promote beneficial neuroplasticity and axonal sprouting.  
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1.7 Augmenting neuroplasticity to enhance recovery from CNS injury:  
 Examples from the literature 
 This strategy to improve recovery has been explored in animal models of a 
number of different CNS injuries, and most commonly in spinal cord injury (SCI).  For 
example, Huang et al used myelin immunization in mice to stimulate the creation of 
polyclonal antibodies to block myelin-associated axonal growth inhibitors.  This resulted 
in increased CNS axonal growth and regeneration in mice after SCI, and corresponding 
improvements in hind leg function (Huang, McKerracher et al. 1999).   In a similar 
fashion, anti-Nogo antibodies, as well as peptide antagonists of Nogo-66 (which bind to 
the Nogo receptor) have been used to augment axonal growth and the neuroplastic 
response to improve functional recovery in rodent models of SCI (Schnell and Schwab 
1990; Bregman, Kunkel-Bagden et al. 1995; Brosamle, Huber et al. 2000; GrandPre, Li et 
al. 2002; Li and Strittmatter 2003).  Related strategies have been implemented in studies 
with animal models of stroke.  For example, Papadapolous, Tsai et al used an antibody to 
block the inhibitory protein Nogo-A in rats after middle cerebral artery occlusion (a 
model of ischemic stroke), and observed increased axonal growth and functional recovery 
in the treated animals (Papadopoulos, Tsai et al. 2002).  Lee, Kim et al employed genetic 
(hetero-and homozygous Nogo receptor knockouts) as well as pharmacologic methods to 
diminish the Nogo-Nogo receptor system in rodents.  Using rodent models of stroke, they 
found in both cases that axonal plasticity and behavioural function were enhanced after 
stroke when compared to control animals (Lee, Kim et al. 2004). 
 Perhaps most pertinent to this study is research that focuses on decreasing levels 
of CSPGs in an attempt to improve neuronal plasticity and recovery after CNS injury.  
One popular technique is to administer Chondroitinase ABC (ChABC): a bacterial 
enzyme that catalyzes the degradation of CSPGs by cleaving off glycosaminoglycan 
chains. Besides numerous in vitro studies demonstrating ChABC's ability to degrade 
CSPGs and increase axonal plasticity, many proof of principle in vivo studies have been 
done with ChABC as well  (Fidler, Schuette et al. 1999; Schmalfeldt, Bandtlow et al. 
2000).   For example, although not a model of a common human CNS injury, treating 
mice with ChABC at the lesion site after performing a unilateral nigrostriatal axotomy on 
them was found to improve neuroplasticity.  By diminishing inhibitory CSPG 
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accumulation, the full development of a glial scar was prevented, which allowed axons to 
extend across the lesion (Li, Homma et al. 2007).  As with other strategies to improve 
neuroplasticity, the use of ChABC has been examined in more complex CNS injuries, 
like SCI.  Bradbury, Moon et al treated spinal cord injured rats with intrathecal injections 
of ChABC at the level of the lesion.  This led to the degradation of CSPGs at the injury 
site, and a consequent increase in neurite growth-associated proteins in injured neurons.  
Tract tracing experiments also displayed regeneration of both ascending and descending 
spinal axons. Electrophysiological tests highlighted the restoration of post-synaptic 
activity below the lesion with ChABC treatment.  All findings correlated with improved 
locomotor and proprioceptive functional recovery in the ChABC treated rats, 
emphasizing the therapeutic potential of targeting CSPGS in the injured CNS (Bradbury, 
Moon et al. 2002).  
 One recent and particularly relevant study involves ChABC treatment in a rat 
model of stroke (Soleman, Yip et al. 2012).  Unlike other investigations of stroke 
therapies in rodents that often target the lesioned area itself, Soleman et al concentrated 
on more remote CNS areas for ChABC treatment. By administering ChABC into the 
denervated side of the cervical spinal cord (relevant for forelimb function) 3 days post-
stroke, they hoped to induce localized plasticity of the spinal circuitry.  Histological 
analysis of the cervical spinal cord one week after ChABC injection showed unilateral 
degradation of CSPGs, and reduced peri-neuronal net presence (by use of 2B6 and WFA 
antibodies, respectively).  Histological analysis of anterograde tract-tracing (by injecting 
BDA into the contralesional motor cortex) in the cervical spinal cord showed an increase 
in BDA-labeled collaterals sprouting on the deafferented side in ChABC-treated animals.  
In accordance with increased neuroplasticity, they found that ChABC treatment also 
significantly improved forelimb motor recovery by use of the staircase and cylinder tests, 
as well as forelimb sensory recovery with a bilateral tactile stimulation test (Soleman, 
Yip et al. 2012). 
 Thus, a number of studies have shown that a decrease in CSPGs creates a CNS 
environment that encourages neurite-growth, reactivates plasticity, and promotes 
functional recovery within the CNS after a number of injuries, including stroke.  
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Although ChABC treatment may seem promising, the actual process of injecting the CNS 
tissue is challenging and invasive, and treatment is limited to the areas surrounding the 
injection sites.  ChABC also has the major disadvantage of being unable to completely 
digest the glycosaminoglycan chains from the core protein of CSPGs (Caterson, Christner 
et al. 1985).  This leaves carbohydrate "stubs" behind, which are less inhibitory to neurite 
growth than the complete chains, but which can still reduce axon regeneration ability 
(Lemons, Sandy et al. 2003). Therefore it would be beneficial to investigate methods to 
prevent the increased production of CSPGs after CNS injury. 
 One such investigation by Grimpe, Silver et al used a ribozyme-based strategy to 
target xylosyltransferase-I (XT-I), an enzyme involved in CSPG production that initiates 
the synthesis of chondroitin sulfate side chains.  By decreasing XT-I messenger RNA, 
they were able to show a strong reduction in the levels of inhibitory GAG chains in the 
rodent lesion penumbra after SCI, which led to the regeneration of axons well beyond the 
core lesion (Grimpe and Silver 2004).  However, like with ChABC, the delivery of this 
ribozyme is also limited to the areas surrounding the injection site.  Therefore, it would 
be beneficial to investigate how decreasing CSPGs in a more global manner in the CNS 
could affect recovery after CNS injury as well.  
 
1.8 The role of the transcription factor SOX9 in the post-stroke CNS 
 To target CSPGs on a more global CNS basis, it is important to understand the 
process of CSPG production.  Synthesis of the chondroitin sulfate side chains is initiated 
by adding xylose to a serine component of the core protein.   This is the rate-limiting step 
in the production of chondroitin sulfate side chains, and is completed by the enzyme 
xylosyltransferase (XT, as mentioned previously).  XT exists in two isoforms that are 
encoded by two different genes, XT-I and XT-II (Schwartz 1977; Kearns, Campbell et al. 
1991; Gotting, Kuhn et al. 2000).  Next, these side chains are sulfated by either 
chondroitin 4-sulfotransferase (C4ST) (Yamauchi, Mita et al. 2000), or chondroitin 6-
sulfotransferase (C6ST), (Fukuta, Uchimura et al. 1995).  However, C4ST is the main 
type present in astrocytes (Gallo and Bertolotto 1990).   Our lab has identified the 
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transcription factor SOX9 as being responsible for upregulating the expression of XT-I, 
XT-II, and C4ST with bioinformatics and in vitro studies (Gris, Tighe et al. 2007).  
Unpublished chromatin immunoprecipitation experimental data confirms that the 
regulation is likely direct.  This discovery led our lab to develop the hypothesis that 
SOX9 inhibition after a CNS injury would lead to decreased CSPG production, and 
consequently, a microenvironment that better promotes nerve growth and neurological 
recovery.  
 Sox9 is part of a family of transcription factors composed of 20 different genes, 
all with a high mobility group (HMG-box) DNA binding domain of similar sequence 
homology to that of the Y chromosome-encoded testis determining factor SRY (Moniot, 
Declosmenil et al. 2009).  Sox9 plays a critical role in sex determination, and in nervous 
system development.  Since conventional Sox9 knockout mice do not survive perinatally 
(Bi, Huang et al. 2001), it was necessary to use a conditional Sox9 knockout line of mice 
to study the role of SOX9 in recovery from CNS injury (Outlined in 2.1 of Methods and 
Materials).   
  We have studied the role of SOX9 after spinal cord injury for several years now 
by crossing mice obtained from Dr. Andreas Schedl (mice with floxed Sox9 alleles) with 
mice obtained from Jackson Laboratories (mice with Cre-recombinase fused to the 
mutated ligand binding domain of the human estrogen receptor).  The resulting mouse 
line containing both floxed Sox9 and Cre recombinase allowed us to examine the 
molecular, cellular, and neurological responses to spinal cord injury in which SOX9 
expression levels were reduced in all cell types.  It was confirmed that these mice did, in 
fact, exhibit significantly lower levels of Sox9 mRNA and protein with real-time PCR 
and western blot analyses (McKillop, Dragan et al. 2013).  After inducing a 70 kdyne 
contusion spinal cord injury in the mice, Sox9 knockout mice experienced improved 
recovery in hind limb functioned as measured by the Basso mouse scale (BMS), which 
examines ankle movement and walking ability.  Using rodent activity boxes, it was found 
that Sox9 knockout mice locomoted to a greater extent than the control mice after injury.   
Improvements in functional recovery were associated with reduced astrocytic activation 
as well as lower CSPG levels at the lesion site in Sox9 knockout animals compared to 
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control animals (McKillop, Dragan et al. 2013).  Success with improving function after 
SCI in mice led us to consider applying Sox9 ablation in other models of CNS injury.  
Hence, similar studies to examine the effects of Sox9 ablation in a mouse model of stroke 
were carried out.   
 
1.9 Preliminary work on Sox9 ablation in a mouse model of stroke  
 Prior to this study, Dr. Kathy Xu of the Brown lab had done preliminary work 
characterizing the effects of conditional Sox9 ablation in a mouse model of stroke.  Since 
ischemic stroke in human patients usually results from a thrombotic or embolic occlusion 
in a major cerebral artery, and most often the middle cerebral artery (MCA), a commonly 
used method to reproduce stroke in animals is to occlude temporarily the MCA (Durukan 
and Tatlisumak 2007; Liu and McCullough 2011) . As such, MCAO (middle cerebral 
artery occlusion) is the stroke model used in this study.  The following preliminary 
findings are currently unpublished. To begin, all animals underwent surgical intra-arterial 
suture occlusion of the middle cerebral artery through the internal carotid artery.  The 
suture was removed 30 minutes later, which allowed reperfusion of the affected area.  
This injury model causes rapid infarction of the striatum, and delayed infarction in the 
overlying cortex (Carmichael 2005).  Longer occlusion times can lead to widespread 
malignant infarction in the rodent brain, which does not model the most common cases of 
human stroke (Carmichael 2005). 
 To ensure that the size and area of the infarcts produced after MCAO were equal 
among Sox9 knockout and control animals, 2,3,5-triphenyltetrazolium chloride (TTC) 
staining was performed on the animals' brains 24 hours after injury.  The infarct volumes 
were found to be statistically equivalent between groups, indicating that equal injuries 
were being produced after the 30 minute MCAO.  After ensuring an equal injury, 
histological, western blot, and densitometric analyses confirmed that SOX9 protein levels 
were significantly reduced in the brains of the Sox9 KO animals when compared to 
controls two weeks after MCAO (more pronounced on the side of the brain ipsilateral to 
injury).  Next, it was logical to examine if this reduction in SOX9 affected CSPG levels 
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in the injured central nervous systems of both sets of mice.  CSPG levels of the diffuse 
ECM, as well as levels of the CSPG-rich highly condensed matrix structures called peri-
neuronal nets were examined two weeks after MCAO (using CS56, and WFA antibodies, 
respectively).  Histological, western blot and densitometric analyses of CS56 two weeks 
post-MCAO showed a significant reduction of diffuse extra-cellular matrix CSPGs in the 
striata of Sox9 KO mice compared to controls (again, even more profoundly on the side 
ipsilateral to injury).   
 Levels of synapse-stabilizing PNNs were examined at more remote CNS areas 
that are particularly relevant to motor function in the mouse: the red nucleus (a midbrain 
neuronal cluster that plays an important role in locomotion and skilled limb movements) 
(Muir and Whishaw 2000), and the ventral horn of the cervical spinal cord (where motor 
neurons controlling forelimb functions receive input from the brain) (Lemon 2008).  In 
both cases, histological and immunoreactivity imaging analyses confirmed that PNN 
levels (examined with wisteria floribunda agglutin or WFA) were significantly lower on 
the deafferented sides of both the red nucleus and cervical spinal cord of the Sox9 
knockout mice compared to controls two weeks after MCAO.  Altogether, these data 
show that our tamoxifen-inducible conditional Sox9 knockout model works as 
hypothesized, in that SOX9 and CSPG levels are significantly reduced in the CNS after 
stroke.  This study focuses on answering important follow-up questions to these 
preliminary finding:  How does the ablation of Sox9 and the consequent reduction in 
CSPG and PNN levels in the CNS affect neuroplasticity and functional recovery after 
stroke? 
 
1.10 Background Summary and Rationale  
 Ischemic stroke is a detrimental vascular occurrence in which blood flow to the 
brain is interrupted. It is a leading cause of death and disability worldwide, and requires 
further investigation into better avenues for treatment.  Recovery can occur after a stroke, 
but is often limited, and will plateau after about 6 months.  Any recovery that does occur 
is generally attributed to neuroplasticity: the central nervous system's ability to 
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reconfigure in an attempt to take over for lost and damaged functions.  Something that 
limits this post-stroke neuroplasticity is the expression of extracellular matrix molecules 
called chondroitin sulfate proteoglycans (CSPGs).  CSPGs can act as physical and 
molecular barriers to neuronal growth, and are also a component of highly condensed 
matrix structures called peri-neuronal nets, which stabilize synapses and limits 
neuroplasticity.  Our research group has identified the transcription factor SOX9 as 
responsible for upregulating the expression of CSPGs in the injured brain.  We 
hypothesized that by conditionally knocking out the gene Sox9 in mice, the expression of 
CSPGs would decrease.  This would create a CNS microenvironment that is more 
conducive to neuroplastic events, and in turn, lead to increased neurological recovery 
after stroke.  
To summarize: 
• Normal recovery after stroke, however limited, is generally due to neuroplasticity. 
• CSPGs, the expression of which is upregulated after a CNS injury like stroke, 
inhibit neuroplasticity. 
• Work done in our lab has shown that SOX9 is a transcription factor that increases 
CSPG expression in the injured CNS.  By conditionally knocking out Sox9, we 
can decrease CSPG and peri-neuronal net levels in the mouse CNS. 
• The purpose of this study is to investigate if a decrease in SOX9 and consequently 
CSPG expression will lead to increased neuroplasticity, and in turn, improved 
functional recovery after stroke. 
  
1.11  Hypothesis 
 I hypothesize that conditional ablation of Sox9 in mice will lead to increased 
functional recovery after middle cerebral artery occlusion (a rodent model of 
stroke), and will be accompanied by increased neuroplasticity when compared to 
control mice.  
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1.12  Objectives 
The objectives of this study are to: 
 1)  Investigate the effects of conditional Sox9 ablation in mice on neurological 
 and functional recovery after MCAO compared to control mice (by use of  corner, 
 cylinder, and grip strength tests). 
 2)  Evaluate neuroplasticity after MCAO in mice, and compare between Sox9-
 ablated animals and controls (by use of corticorubral and corticospinal tract 
 tracing, as well as immunohistological examination of synaptic marker 
 expression levels).  
 
1.13 Overview of experimental plan 
 Objectives 1 and 2 are approached using the same experimental timeline.  Using a 
Cre-loxP strategy, both Sox9flox/flox;Cre and Sox9flox/flox mice are administered tamoxifen to 
induce Sox9 ablation in the Sox9flox/flox;Cre mice.  This Cre-LoxP strategy is outlined in 
Figure 1.  After tamoxifen administration, a one-week washout period occurs to allow 
recombination to occur, and for tamoxifen to leave the system. During this week, pre-
injury behavioural test data are acquired.  Thereafter, both sets of mice undergo left-sided 
MCAO surgery. A small number of animals of both genotypes are subjected to sham 
surgeries, to serve as another type of control.  Data for Objective 1 are obtained by doing 
behavioural testing with the mice (corner, cylinder, and grip strength tests) for the 
subsequent 4 weeks, and comparing results between Sox9-ablated animals and controls.  
Next, a tract tracing experiment begins in the same animals by injecting BDA into the 
right (unaffected) motor cortex.  Two weeks later, the animals are perfused and the brain 
and spinal cord tissues are sectioned to use for histological analysis.   
 For Objective 2, neuroplasticity is evaluated at two areas of the central nervous 
system that are important for the motor functions analyzed in the behavioural tests: the 
red nucleus within the brain, and the cervical enlargement of the spinal cord.  To evaluate 
structural neuroplasticity, BDA is injected into the right motor cortex (uninjured side) 
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and BDA-labeled fibers on both sides of the red nucleus and cervical spinal cord are 
counted.  The number of BDA-labeled fibers on the deafferented side of each CNS 
location is normalized to the number of fibers on the opposite side (to control for labeling 
efficiency), and results are compared between Sox9-ablated and control animals.  To 
examine putative synaptic neuroplasticity, immunohistochemistry is used to stain for 
glutamatergic synaptic markers (vesicular glutamate transporter 1 and 2, or VGLUT1 and 
VGLUT2).   On the deafferented side of each area (left-sided red nucleus and right-sided 
cervical spinal cord), signal over background levels of VGLUT staining is calculated, (as 
area/area or volume/volume) and compared between Sox9-ablated and control animals.  
Results for sham animals are also assessed.  To add a more acute post-injury time point to 
the red nucleus VGLUT1 and VGLUT2 data, brain sections from a previous experiment 
in which both Sox9flox/flox;Cre and Sox9flox/flox animals were perfused 48 hours after MCAO 
are also used. 
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Figure 1:  A schematic representation of the Cre-loxP strategy to knockout the Sox9 
gene.  In Sox9flox/flox;Cre mice, the administration of tamoxifen (TM) releases heat-shock 
protein 90 from the Cre-ER protein complex, allowing it to enter the nucleus of the cell.  
Exons 2 and 3 of the Sox9 gene between the loxP sites are excised, effectively preventing 
SOX9 expression.  Tamoxifen is also administered to the Sox9flox/flox mice; however, there 
is no Cre-ER present within the cells to excise the Sox9 gene, so SOX9 expression is 
normal. 
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 Cellular mechanism for conditional Sox9 knockout 
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Chapter 2: 
 
Materials and Methods 
2.1  Animals 
 Conventional Sox9 knockout mouse embryos (homozygous and heterozygous, 
Sox9-/- and Sox9+/-, respectively) are not viable (Bi, Huang et al. 2001).  As such, a 
tamoxifen-inducible conditional Sox9 knockout strategy was used to allow the mice to 
progress through development with normal SOX9 activity.  We bred a mouse strain 
(obtained from Dr. Andreas Schedl) carrying floxed Sox9 alleles (exons 2 and 3 of Sox9 
surrounded by loxP sites) (Akiyama, Chaboissier et al. 2002) with a transgenic mouse 
line ubiquitously expressing Cre recombinase fused to the mutated ligand binding domain 
of the human estrogen receptor (ER) under the control of a chimeric cytomeglovirus 
(CMV) immediate-early enhancer/chicken ß-actin promotor (B6.Cg-Tg(CAG-Cre / 
Esr1)5Amc / J)) (Jackson Laboratories, Bar Harbor, ME).  The two populations of 
resulting offspring served as tamoxifen-inducible Sox9 knockout mice 
(Sox9flox/flox;CAGGCreER, here after referred to as  Sox9flox/flox;Cre), and control mice with 
normal expression levels of Sox9 (Sox9flox/flox).  Polymerase chain reaction analysis was 
used to genotype the animals using the following primers: 
Sox9flox allele: 5’-ACACAGCATAGGCTACCTG-3’ and                                                
5’-GGTAATGAGTCATACACAGTAC-3’.  
Sox9wildtype allele: 5’ GGGGCTTGTCTCCTTCAGAG-3’ and                                         
5’-TGGTAATGAGTCATACACAGTAC-3’.  
Sox9knock-out allele: 5’-GTCAAGCGACCCATG-3’ and                                                     
5’-TGGTAATGAGTCATACACAGTAC-3’.  
Cre+ allele: 5’-CAATTTACTGACCGTACAC-3’ and                                                     
5’-AGCTGGCCCAAATGTTGCTG-3’.  
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2.2  Tamoxifen administration 
  Both Sox9flox/flox;Cre and Sox9flox/flox mice were administered tamoxifen (Sigma 
Aldrich, St. Louis, MO) by oral gavage at a dose of 3 mg/20 g mouse.  The drug was 
given once a day for 7 days, followed by a 7 day period without treatment (to allow for 
Cre-mediated recombination and tamoxifen clearance to occur before MCAO surgery).  
 
2.3  Induction of focal cerebral ischemia 
 All protocols for these experiments were approved by the University of Western 
Ontario Animal Care Committee in accordance with the policies established in the Guide 
to Care and Use of Experimental Animals prepared by the Canadian Council on Animal 
Care.  Male mice weighing 25-30g were allowed free access to food and water. One week 
after the last dose of tamoxifen was administered, mice were anesthetized with 4% 
isofluorane and maintained at 1.5% isofluorane and 30% O2.  Body temperature was 
maintained using a heating pad.  Cerebral ischemia was induced using an intraluminal 
filament technique (protocol outlined by (Rupadevi, Parasuraman et al. 2011). A midline 
neck incision was made and left common and external carotid arteries were isolated and 
ligated. A 5-0 nylon monofilament coated with 0.1% poly-l-lysine was introduced 
through a small incision into the common carotid artery and advanced to the carotid 
bifurcation for middle cerebral artery occlusion (MCAO).  Reperfusion was initiated 30 
minutes later by monofilament withdrawal.  The mortality rate for these mice was 
approximately 15%.  In sham-operated animals, the monofilament was placed into the 
MCA and withdrawn immediately.  Animals were administered Baytril (25 mg/kg, 
Bayer, Toronto, Ontario, Canada) and bupenorphrine (0.01 mg/kg, Schering-Plough, 
Hertfordshire, UK) subcutaneously after MCAO, and then twice daily for three days after 
the surgery.  If mice showed no signs of functional deficits (circling, etc.) after the 30 
minute MCAO, they were not included in the study. 
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2.4   Measurement of local cerebral blood flow using Laser Doppler 
 Flowmetry  
 Laser Doppler Flowmetry was used to measure cerebral blood flow and verify 
that MCAO had occurred.  This test was done on a separate set of animals to ensure the 
reproducibility of the MCAO (n=3).  The OXYLAB flowmeter is equipped with a small-
caliber probe of 0.7mm diameter (Oxford Optronix, Oxford, UK). The mice were placed 
in a sterotaxic frame with a mouse holder, and anesthetized with 4% isoflurane and 
maintained at 1.5% isoflurane and 30% O2.  Body temperature was monitored and 
maintained using a heating pad.  A midline incision was made and a burr-hole (0.7 mm in 
diameter) was drilled 1mm posterior and 4mm lateral to the sagittal suture on the left side 
of the skull. The probe was held in a micromanipulator and was stereotaxically advanced 
to gently touch the dura covering the ischemic core region. Warm saline (37°C) was 
slowly rinsed around the probe and maintained a clear medium between the probe and the 
dura during the measurement. Stable baseline laser doppler flowmetry readings were 
obtained prior to MCAO surgery. The changes of regional CBF were recorded 5 minutes 
into the occlusion of the middle cerebral artery. A sharp drop over 85% (85.8±2.5%) of 
baseline was noted, which remained stable throughout the 30 minute occlusion.     
 
2.5   Behaviour: functional neurological tests 
2.5.1 Corner test 
 Initially designed by Schallert et al (1982) for rats and later adapted by Zhang et 
al (2002) to mice, the corner test is used to detect sensori-motor and postural 
asymmetries  The apparatus consists of a corner made by two vertical boards 
(30 × 20 × 1 cm3) attached on one side with an angle of 30°. A small opening between 
the boards encourages the mouse to go into the corner. Each mouse is placed at the entry 
of the corner facing into it. When the mouse reaches the wedge of the corner, both sides 
of the body (vibrissae, skin) are stimulated simultaneously. Then, the mouse typically 
rears, and turns either to the right or to the left to exit the corner.  Corner tests were 
carried out  before injury, as well as 2 days afterward, and once per week for four weeks 
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following MCAO surgery.  During each test, the mice were tested ten times (about 2 
minutes per animal), and the chosen sides were noted.  In case of ventral turning (i.e. 
when the mouse turned without rearing), the trial was not taken into account but repeated 
at the end of the session.   
 
2.5.2 Cylinder test 
 The cylinder test was initially used in rats and later adapted for use in mice to 
assess forelimb use asymmetry (Schallert, Fleming et al. 2000; Li, Blizzard et al. 2004). 
The mice are placed in a transparent cylinder  (9 cm in diameter and 15 cm in height) and 
videotaped during the test. A mirror is placed behind the cylinder with an angle to enable 
the observer to record forelimb movements when the mouse is turned away from the 
camera. After the mouse is put into the cylinder, forelimb use of the first contact against 
the wall after rearing, and during lateral exploration, is recorded by the following criteria: 
(1) The first forelimb to contact the wall during a full rear is recorded as an independent 
wall placement for that limb. (2) Simultaneous use of both the left and right forelimb by 
contacting the wall of the cylinder during a full rear and for lateral movements along the 
wall is recorded as a ‘‘both’’ movement. (3) After the first forelimb (for example right 
forelimb) contacts the wall and then the other forelimb is placed on the wall, but the right 
forelimb is not removed from the wall, a ‘‘right forelimb independent’’ movement and a 
‘‘both’’ movement are recorded. A minimum of 20 movements are recorded during the 
three minute test. If the mouse did not complete 20 forelimb placements, a second trial 
was performed later that day.  If 20 forelimb placements could not be recorded again, the 
animal was not included in the study. 
 Cylinder tests occurred three days after injury, as well as once a week for four 
weeks following MCAO surgery.  The asymmetry score for each test day is calculated as: 
(non-impaired forelimb movement - impaired forelimb movement) / (non-impaired 
forelimb movement + impaired forelimb movement + both movement) as previously 
described in the rat (Schallert, Fleming et al. 2000).  This test evaluates forelimb use 
asymmetry for weight shifting during vertical exploration and provides high inter-rater 
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reliability, even with inexperienced raters. Occasionally, mice with large deficits did not 
move frequently enough to obtain an adequate number of vertical movements.   
 
2.5.3 Grip strength test 
 The grip strength test was performed using a Grip Strength Meter (Columbus 
Instrument, Columbus, OH).  It employs a triangular steel wire that the animal 
instinctively grasps. When pulled by the tail, the animal exerts force on the steel wire 
(Kilic, ElAli et al. 2010).  The left forepaw is wrapped with adhesive tape so that grip 
strength in the right forepaw (affected by the left-sided MCAO) could be evaluated. Grip 
strength was measured five times in each test, and the highest score was recorded.  Grip 
strength was measured before the MCAO surgery, and then once a week afterwards for 
four weeks. From these data, percentage values for each week post-MCAO measurement 
compared to the initial pre-MCAO recording were calculated.  If mice consistently failed 
to grab the steel wire for the proper acquisition of a grip-strength reading, they were not 
included in the study. 
 
2.6  Delivery of biotinylated dextran amines (BDA) 
 The protocol for anterograde axonal tract tracing in rats had been established 
previously (O'Neill and Clemens 2001).  Here, we adopted this method to mice. Four 
weeks after MCAO, the mice were placed in a sterotaxic frame with a mouse holder, and 
anesthetized with 4% isoflurane and maintained at 1.5% isoflurane and 30% O2.  Body 
temperature was monitored and maintained at 36ºC using a heating pad and rectal 
thermometer.  A small piece of skull (1.5mm in diameter) overlaying the right motor 
cortex was removed. A total volume of 1.6µl 10% BDA (10,000 MW, Molecular Probes) 
was administered to each animal, using a Hamilton microsyringe, paired with a 33G 
needle. Four equal injections were administered to cover the forelimb representation area 
in the motor cortex, contralateral to the stroke, located at 0.5mm anterior and posterior to 
the bregma; 1.5mm and 2.5mm lateral to the sagittal suture, respectively, at a depth of 
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0.5mm. The needle was kept in place after injection for at least 2 minutes to avoid the 
leakage from the injection site.  After all four injections, the incision was sutured.  
Animals were administered Baytril (25 mg/kg, Bayer, Toronto, Ontario, Canada) and 
bupenorphrine (0.01 mg/kg, Schering-Plough, Hertfordshire, UK) subcutaneously after 
the surgery, and then twice daily for three days.   
 
2.7  Perfusions 
  Three weeks post-BDA injection, the mice were deeply anesthetized with 100 
mg/kg ketamine: 5 mg/kg xylazine, and transcardially perfused with ice cold saline 
solution, followed by 4% paraformaldehyde (4% PFA in 0.1 M phosphate buffer at pH 
7.4).  The experimental timeline is shown in Figure 2.  Brains and spinal cords were 
dissected, post-fixed in 4% PFA for 1 hour, and then cryoprotected in 20% sucrose at 4ºC 
overnight.  Brains and spinal cords were dissected and embedded in Tissue Tek O.C.T. 
Compound (Sakura Finetek USA Inc., Torrance, CA), frozen over dry ice and stored at -
80ºC.  The brains were cross sectioned at 10µm using a cryostat, and serially thaw-
mounted on SuperfrostTM glass slides (Fisher Scientific Company, Ottawa, Canada).  
Collected brain sections alternated on 10 slides with 5 sections per slide so each section 
per slide was separated by 100µm.  Cervical spinal cords were cross sectioned at 10µm 
using a cryostat, and serially thaw-mounted on SuperfrostTM glass slides (Fisher 
Scientific Company, Ottawa, Canada) as well.  Collected cervical spinal cord transverse 
sections alternated on 10 slides with 10 sections per slide so that each section per slide 
was separated by 100µm.   
 To add a more acute post-injury time point to the red nucleus glutamatergic input 
data (VGLUT1 and VGLUT2, as described in section 2.9) brain sections from 
Sox9flox/flox;Cre and Sox9flox/flox animals that were perfused 48 hours after MCAO were also 
used.  The experimental timeline for these animals is also shown in Figure 2.  Brains 
were dissected, sectioned and serially thaw-mounted in the manner described above. 
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Figure 2: Experimental timelines for both experiments discussed in this thesis   
A) Timeline for the MCAO experiment, with behavioural analyses and an anterograde 
neuronal tracer injection into the contralesional motor cortex.  The two groups of mice used 
include the ubiquitous Sox9 knockout mice (Sox9flox/flox;Cre-ER) and their littermate 
controls (Sox9flox/flox). 
B) Timeline for the MCAO experiment in which both the ubiquitous Sox9 knockout mice 
(Sox9flox/flox;Cre-ER) and their littermate controls (Sox9flox/flox) were sacrificed 48 hours 
after MCAO.  The brain tissue was used to contribute to the VGLUT quantification data. 
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A     Timeline for MCAO experiment, including behavioural analyses and 
BDA injection in control and Sox9 knockout mice  
 
 
 
  
B            Timeline for past MCAO experiment with 48 hour post-surgery                    
sacrifice in control and Sox9 knockout mice 
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2.8 Immunohistochemistry and analysis for biotinylated dextran amines 
 
2.8.1 Immunohistochemistry for biotinylated dextran amines (BDA)  
 Brain and cervical spinal cord sections were washed three times for 10 minutes in 
TBS, and then incubated with 0.3% hydrogen peroxide in methanol for 30 minutes to 
quench the endogenous peroxidase activity.  After three more TBS washes, the sections 
were incubated in blocking solution (5% milk, 1% bovine serum albumin, and 0.3% 
Triton X-100 in TBS) for 1 hour.  Another set of TBS washes followed, and then the 
sections were incubated with avidin-biotin-peroxidase complex (ABC Elite; Vector 
Laboratories, Burlingame, CA, USA) in TBS with 0.5% Triton X-100 for 2 hours.   After 
a final set of TBS washes, staining was revealed with a 3,3'-diaminobenxidine reaction 
(DAB, Invitrogen, Carlsbad, CA).  Sections were then washed in dH20, dehydrated, and 
protected with a coverslip using XYL mounting medium (Fisher Scientific Company, 
Ottawa, Canada). 
 
2.8.2 Analysis of corticorubral projections  
 Three coronal sections at the level of the parvocellular red nucleus (at least 100 
µm apart) were examined to evaluate the corticorubral projections.   Images of each 
section were captured with a 10X and a 20X objective lens (Olympus BX50).   First, the 
labeled fibers from all three sections in the contralesional hemisphere (ipsilateral to BDA 
injection) projecting to the red nucleus were counted.    For each section, the fibers 
present on the ipsilesional side (contralateral to BDA injection) were quantified and 
normalized to the total number of the labeled fibers on the contralesional side (to control 
for labeling efficiency).  Fiber numbers were quantified by two separate raters (myself 
and Dr. Kathy Xu), and then averaged to obtain the final fiber counts.  Fibers had to have 
a minimum length of 3µm to be counted. Only the animals that had more than 100 
labeled fibers on the contralesional side using the 10X objective were included to ensure 
adequate labeling efficiency. 
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2.8.3 Analysis of corticospinal projections  
 Eight transverse spinal cord sections at the level of cervical enlargement (at least 
100 µm apart) were examined to evaluate the corticospinal projections.  Images of each 
section were captured with a 10X and a 20X objective lens (Olympus BX50).   To begin, 
in all eight cervical spinal cord sections, the labeled fibers in the grey matter on the 
contralesional side (ipsilateral to BDA injection) were counted. For each section, the 
fibers present within the grey matter of the contralesional side of the cervical spinal cord 
(ipislateral to BDA injection) were quantified and normalized to the total number of the 
labeled fibers on the ipsilesional side (to control for labeling efficiency). Fiber numbers 
were quantified by two separate raters (myself and Dr. Kathy Xu), and then averaged to 
obtain the final fiber counts.  Fibers had to have a minimum length of 3µm to be counted. 
Only the animals that had more than 100 labeled fibers on the ipsilesional side using the 
10X objective were included to ensure adequate labeling efficiency.   
 
2.9 Immunohistochemistry and analysis for glutamatergic input markers 
 VGLUT1 and VGLUT2 at the level of the ipsilesional red nucleus 
 
2.9.1 Immunohistochemistry for VGLUT1, VGLUT2 and SMI-32  
 SMI-32 is an antibody for a non-phosphorylated epitope in neurofilament heavy 
polypeptide, which is found within the neuronal cell bodies, dendrites, and some thick 
axons of rubrospinal cells in the red nucleus  (Liang, Paxinos et al. 2012).  This antibody 
was used to identify the location of the red nucleus. VGLUT1 and VGLUT2 antibodies 
were used to stain for vesicular glutamate transporter 1, and 2, respectively (markers of 
glutamate transporters in the membranes of synaptic vesicles).  VGLUT1 is the major 
glutamate transporter expressed in layer V motor cortex neurons (including corticorubral) 
, while VGLUT2 is the major glutamate transporter in cerebellar and thalamic projections 
to the red nucleus (Allen Brain Atlas - VGlut2 in mouse brain; Allen Brain Atlas - 
VGlut1 in mouse brain; Naus, Flumerfelt et al. 1986; Roger and Cadusseau 1987; 
Arnault, Ebrahimi-Gaillard et al. 1994; Varoqui, Schafer et al. 2002; Fink, Englund et al. 
2006; Barroso-Chinea, Castle et al. 2007). 
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 Brain sections from Sox9flox/flox;Cre and Sox9flox/flox mice were incubated with 
blocking solution (5% goat serum in PBS, with 0.1% Triton X-100) at room temperature 
for 2 hours, and then incubated with primary antibodies diluted in blocking solution at 
4ºC overnight.  The primary antibodies used were:  mouse anti-SMI-32 (1:1000, 
Covance, catalogue # SMI-32R), along with either rabbit anti-VGLUT1 (1:500, Synaptic 
Systems, catalogue # 135 302) or rabbit anti-VGLUT2 (1:500, Synaptic Systems, 
catalogue # 135 402).  Sections were washed three times for 10 minutes, after which 
immunofluorescent labeling was performed using the following secondary antibodies (for 
one hour at room temperature): Alexa Fluor 488 goat anti-mouse IgG (1:500, Life 
Technologies, catalogue # A-11029), and Alexa Fluor 647 goat anti-rabbit (1:1000, Life 
Technologies, catalogue # A-21244).  After washing three times in PBS for at least 30 
minutes, the sections were protected with a coverslip using ProLong Gold Anti-Fade 
mounting medium with DAPI (Life Technologies, catalogue # P36935).   
 
2.9.2 Analysis of glutamatergic input markers VGLUT1 and VGLUT2 at the 
 level of the ipsilesional red nucleus 
 Three coronal sections at the level of the parvocellular red nucleus (at least 100 
µm apart) were examined to evaluate levels of presynaptic glutamatergic markers within 
the ipsilesional red nucleus (three sections each for both VGLUT1 and VGLUT2).  Z-
stacks 2 µm in thickness (composed of 10 sections at a thickness of 0.2µm) were 
captured with a 40X objective lens with a spinning disk confocal microscope and 
Volocity software (CSU10, with an Olympus IXS1).  Images were deconvoluted with 
Autoquant X software (Media Cybernetics Inc., Rockville, MD, USA).   Using Imaris 
software (Bitplane AG, Zurich, Switzerland) VGLUT1 and VGLUT2 signal greater than 
background within the red nucleus was identified and quantified (as volume of 
immunoreactivity/volume of red nucleus section).  Average VGLUT1 and VGLUT2  
immunoreactivity levels (volume/volume) were determined for each animal.  
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2.10 Immunohistochemistry and analysis for glutamatergic input marker 
 VGLUT1 at the level of the contralesional cervical spinal cord 
 
2.10.1 Immunohistochemistry for VGLUT1 and NeuN 
 Vesicular glutamate transporter 1 (VGLUT1) is the major glutamate transporter 
present in corticospinal cells (Varoqui, Schafer et al. 2002), whereas NeuN serves as a 
general neuronal marker (a neuronal specific nuclear protein in vertebrates) to aid in 
locating the ventral horn  (Varoqui, Schafer et al. 2002). Cervical spinal cord sections 
from Sox9flox/flox;Cre and Sox9flox/flox mice were incubated with blocking solution (5% 
goat serum in PBS, with 0.1% Triton X-100) at room temperature for 2 hours, and then 
incubated with primary antibodies diluted in blocking solution at 4ºC overnight.  The 
primary antibodies used were:  mouse anti-NeuN (1:200, Millipore, catalogue # 
MAB377), and rabbit anti-VGLUT1 (1:500, Synaptic Systems, catalogue # 135 302).  
Sections were washed three times for 10 minutes, after which immunofluorescent 
labeling was performed using the following secondary antibodies (for one hour at room 
temperature): Alexa Fluor 488 goat anti-mouse IgG (1:500, Life Technologies, catalogue 
# A-11029), and Alexa Fluor 594 goat anti-rabbit (1:1000, Life Technologies, catalogue 
# A-11072).  After washing three times in PBS for at least 30 minutes each, the sections 
were protected with a coverslip using ProLong Gold Anti-Fade mounting medium with 
DAPI (Life Technologies, catalogue # P36935).   
 
2.10.2   Analysis of glutamatergic input marker VGLUT1at the level of the    
   contralesional cervical spinal cord 
 Eight transverse spinal cord sections at the level of the cervical enlargement (at 
least 100µm apart) were examined to evaluate levels of VGLUT1 within the 
contralesional cervical spinal cord ventral horns.  Images of each section were captured 
with a 10X objective lens (Olympus BX50).  Using Image Pro Plus software, VGLUT1 
signal greater than background within the ventral horns was identified and quantified (as 
area of immunoreactivity/area of ventral horn section).  An average VGLUT1 
immunoreactivity level (area/area) was determined for each animal.  
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2.11 Immunohistochemistry and fluorescent microscopy for BDA-labeled 
 fibers at the level of the ipsilesional red nucleus  
 
2.11.1   Immunohistochemistry for BDA-labeled fibers at the level of the    
   ipsilesional red nucleus  
 Brain sections from Sox9flox/flox;Cre mice were incubated with blocking solution 
(4% goat serum, 1% bovine serum albumin in PBS, with 0.05% Triton X-100) at room 
temperature for 2 hours, and then incubated with the primary antibody mouse anti-SMI-
32 (1:1000, Covance, catalogue # SMI-32R) diluted in blocking solution at 4ºC 
overnight.  Sections were washed three times for 10 minutes, after which 
immunofluorescent labeling was performed using the following secondary antibodies (for 
one hour at room temperature): Alexa Fluor 488 goat anti-mouse IgG (1:500, Invitrogen, 
catalogue # A11029), and Streptavidin Alexa Fluor 594 conjugate (1:1000, Invitrogen, 
catalogue # S-11227).  After washing three times in PBS for 10 minutes,  0.5% sudan 
black in 70% ethanol was applied to the sections for 90 seconds.   The sections were 
rinsed three times for one minute in 70% ethanol, then washed twice for 5 minutes in 
PBS, and finally protected with a coverslip using ProLong Gold Anti-Fade mounting 
medium with DAPI (Life Technologies, catalogue # P36935).  
 
2.11.2    Microscopy for BDA- labeled fibers at the level of the ipsilesional     
    red nucleus  
  Coronal sections at the level of the parvocellular red nucleus within 
Sox9flox/flox;Cre mice (6 weeks post-MCAO) were examined.  The objective was to 
capture a high quality photomicrograph of a BDA-labeled fiber extending to an SMI-32 
positive cell in the ipsilesional red nucleus (contralateral to the BDA injection).  A 2 µm 
Z-stack (composed of 10 sections at a thickness of 0.2 µm) was captured with a 60X 
objective lens on a confocal microscope (Zeiss LSM 510 Meta).   
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2.12 Statistics 
 Data are presented as the mean ± standard error of the mean (SEM).  Behavioural 
test data were analyzed with two-way repeated measures analysis of variance (ANOVA) 
tests to detect significant effects of genotype and/or time, as well as any interactions.  If a 
significant genotype by time interaction effect was noticed (p≤ 0.05), a post-hoc test 
(Bonferroni) was carried out.  Results obtained from the BDA tract tracing experiments 
were analyzed with Student's t-tests.  In both the corticorubral and corticospinal tract 
analyses, significance was noted when p<0.05.   Vesicular glutamate transporter 
immunohistochemistry results were analyzed with One-way ANOVA tests. If the means 
were determined to be statistically different, a Newman-Keuls post-hoc test was carried 
out to detect significant differences between both genotypes at all time points (p<0.05). 
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Chapter 3: 
 
Results: 
3.1  Effects of Sox9 ablation on functional recovery after MCAO   
 To determine if conditionally knocking out Sox9 in mice had an effect on 
functional recovery after MCAO, three separate behavioural tests were used for 
assessment.  After one week of tamoxifen administration, a one week washout period to 
allow recombination to take place occurred, during which both Sox9flox/flox;Cre and 
Sox9flox/flox mice underwent pre-testing for sensori-motor function to determine baseline 
measurements.  After being subjected to a 30-minute MCAO injury, neurological 
recovery of the mice was measured over the subsequent four weeks using the corner, 
cylinder, and grip strength tests.  
 
3.1.1 Corner test:  Sensori-motor recovery after MCAO was improved in 
 Sox9 knockout mice compared to controls 
 The corner test was used to detect sensori-motor and postural asymmetries.  
Before MCAO surgery, control and Sox9 KO animals made approximately the same 
number of turns on either side (4.83 ± 0.37 and 4.93 ± 0.195 left turns, respectively).  
After receiving a left-sided MCAO, all animals displayed an increase in left turns by two 
days post-surgery.  Considerable sensori-motor recovery was seen as early as one week 
after injury in the Sox9 KO mice, and by two weeks afterward, they had returned to pre-
injury behaviour in which no side preference for turning was noted (7.25 ± 0.494 left 
turns for controls versus 5 ± 0.277 left turns for Sox9 KOs).  A two-way repeated 
measures ANOVA test revealed significant effects of genotype and time (p<0.0001), as 
well as a genotype by time interaction (p=0.0024).  Bonferroni post-hoc analyses showed 
that Sox9 KO mice experienced significantly improved sensori-motor functional recovery 
compared to controls on post-MCAO weeks one through four (p<0.05). 
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Figure 3:  Sox9 KO mice demonstrate improved recovery of sensori-motor function 
following MCAO as observed in the corner test.  All animals subjected to the left-sided 
MCAO showed an increase in left turns by two days post-surgery.  For the Sox9 KO 
animals, functional recovery started as early as one week afterwards, and no side 
preference was noted by the second week. However, in the control group, the progress of 
functional recovery was much slower.  A two-way repeated measures ANOVA revealed 
significant effects of genotype and time (p<0.0001), as well as a genotype by time 
interaction (p=0.0024).  The * symbol denotes a significant difference between genotypes 
by a Bonferroni post-hoc test (p<0.05,  n=12 for Control, n=14 for Sox9 KO). 
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3.1.2 Cylinder test:  Sensori-motor recovery after MCAO was improved in
 Sox9 knockout mice compared to controls 
  The cylinder test was also used to examine sensori-motor function in the mice by 
assessing forelimb use asymmetry.  Figure 4 illustrates the cylinder test results obtained 
between three days to four weeks post-stroke.  Preference for placement of the forelimb 
unaffected by the left-sided MCAO was notable in both groups by three days post-surgery 
(as indicated by a higher asymmetry score).  No preference of forelimb use was observed 
as early as two weeks after MCAO in the Sox9 KO mice (asymmetry score of 0.008 ± 
0.12).  A repeated measurements two-way ANOVA test revealed significant effects of 
genotype (p=0.0061) and time (p<0.0001), but no genotype by time interaction.  Thus the 
Sox9 mice exhibited overall improved sensori-motor functional recovery compared to 
controls.  Pre-MCAO measurements were not recorded for these mice; however, groups of 
uninjured control and Sox9 KO mice were tested afterward, to ensure that neither group 
showed a side preference for turning based solely on genotype (n=5 for both control and 
Sox9 knockout animals, p>0.05 with a Student's t-test; data not shown). 
 
3.1.3 Grip strength test: Recovery of paretic forelimb strength after 
 MCAO was improved in Sox9 knockout mice compared to controls 
  The grip strength test was used to assess strength of the paretic right forelimb 
(innervated by the left hemisphere affected by MCAO).  Figure 5 illustrates the grip 
strength test results obtained before MCAO compared to three days after the surgery, and 
up to four weeks post-MCAO.  Reduction of grip strength was observed in all animals 
three days after surgery.  Sox9 KO mice managed to attain pre-injury grip strength levels of 
the paretic limb over the observed testing period (exhibited 96.75  ± 3.29% of pre-injury 
strength by four weeks post-MCAO, versus 83.11 ± 4.43 % in the control animals).  A 
repeated measurements two-way ANOVA test revealed a global genotype effect (p=0.049) 
and time effect (p<0.0001), but no genotype by time interaction.  Thus the Sox9 mice 
exhibited overall improved recovery of motor function compared to controls. 
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Figure 4:  Sox9 KO mice demonstrate improved recovery of sensori-motor function 
following MCAO as observed in the cylinder test. Main effects of genotype (p=0.0061) and 
time (p<0.0001) were observed with a two-way repeated measures ANOVA test.  The * 
symbol denotes the significant effect of genotype ( n=11 for Control, n=11 for Sox9 KO). 
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   Cylinder Test 
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Figure 5:  Sox9 KO mice demonstrate improved recovery of motor function following 
MCAO as observed in the grip strength test. Main effects of genotype (p=0.049) and time 
(p<0.0001) were observed with a two-way repeated measures ANOVA test.  The * symbol 
denotes the significant effect of genotype ( n=9 for Control, n=8 for Sox9 KO). 
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3.2  Effects of Sox9 ablation on structural neuroplasticity after MCAO   
 To determine if Sox9 ablation in mice had an effect on structural neuroplasticity 
after MCAO, a BDA anterograde tract tracing experiment was used to examine the 
corticorubral and corticospinal tracts originating from the uninjured motor cortex.  BDA-
labeled fibers present at the level of the red nucleus and cervical spinal cord were 
examined and counted six weeks after the MCAO injury.  The denervated side of the red 
nucleus was ipsilateral to the MCAO (ipsilesional), since the corticorubral tract is 
innervates primarily ipsilaterally. Tract tracing studies in uninjured rodents show that 
<1% of fibers cross the midline towards the contralateral red nucleus (when BDA-labeled 
fiber numbers on the contralateral side are normalized to those within the corticospinal 
tract) (Z'Graggen, Metz et al. 1998; Reitmeir, Kilic et al. 2011; Herz, Reitmeir et al. 
2012).  The denervated side of the cervical spinal cord was contralateral to the MCAO 
(contralesional), since the corticospinal tract innervates primarily contralaterally.  Tract 
tracing studies in uninjured rodents show that only 2-4% of the corticospinal neurons of 
the sensori-motor cortex project to the ipsilateral spinal cord (Rouiller, Liang et al. 1991)  
Structural plasticity was assessed by examining numbers of BDA-labeled fibers at the red 
nucleus and cervical spinal cord to see if Sox9 ablation led to increased sprouting of 
motor tract axons into deafferented areas.  
 
3.2.1 Sox9 ablation led to increased structural plasticity in the 
 contralesional corticorubral tract after MCAO 
 Anatomical and physiological studies in mice have shown that the red nucleus 
plays an important role in locomotion through ipsilateral input from the motor cortex, as 
well as connectivity with the spinal cord, cerebellum, and thalamus (Liang, Paxinos et al. 
; Roger and Cadusseau 1987; Jiang, Alheid et al. 2002).  Figure 6A is a schematic 
highlighting the BDA injection into the right motor cortex, and the two corticorubral 
pathways of interest (with the black line representing normal innervation, and the dotted 
line extending to the denervated side).   BDA-labeled fibers at the level of the 
parvocellular red nucleus on both sides were quantified six weeks post-MCAO.  
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 Our results revealed significantly higher numbers of BDA-labeled corticorubral 
fibers present at the ipsilesional (deafferented) red nucleus in Sox9 KO mice by a 
Student's t-test (p<0.05, average of 3.5 ± 1.402 fibers for controls and 11.36 ± 1.588 
fibers for Sox9 KO mice).  In order to control for labeling efficiency differences among 
animals, this number was normalized to the number of BDA-labeled fibers present on the 
contralesional side (which were not significantly different between Sox9 KO and control 
animals).  The resulting percentages of BDA-labeled corticorubral fibers present on the 
ipsilesional side six weeks post-MCAO were significantly higher in the Sox9 KO mice 
compared to control animals.  These results suggest increased structural plasticity in the 
intact corticorubral tract (contralesional) after MCAO in Sox9 KO animals.  Figure 7 
depicts two high quality confocal images of BDA-labeled fibers extending to SMI-32 
positive cells (representative of rubrospinal cells) at the denervated parvocellular red 
nucleus in Sox9 KO mice. 
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Figure 6:  Sox9 KO mice display increased contralesional corticorubral neuroplasticity 
after MCAO compared to control animals.  
A) Biotinylated dextran amine (BDA) was injected into the contralesional motor cortex 
and BDA-labeled fibers were quantified at the level of the parvocellular red nucleus (RN).  
(B-E) Photomicrographs of representative parvocellular red nucleus sections from control 
and Sox9-ablated mice six weeks after MCAO, both contralateral and ipsilateral to the 
BDA injection.  Scale bar in B, D = 25µm. Scale Bar in C, E = 100 µm.  
(F) Quantification of the number of BDA-stained fibers present at the ipsilesional 
parvocellular red nucleus.  The Sox9-ablated mice exhibited significantly higher numbers 
of BDA-labeled fibers on the denervated side compared to control mice as demonstrated 
by a Student's t-test (p<0.05, n=6 for Control, n=8 for Sox9 KO).   (G) Percentages of 
BDA labeled fibers present at the denervated ipsilesional parvocellular red nucleus 
(number of BDA-labeled fibers extending to denervated side normalized to the number of 
BDA-labeled fibers on the contralesional side).  The Sox9-ablated mice exhibited 
significantly higher percentages of BDA-labeled fibers on the denervated side compared 
to control mice as demonstrated by a Student's t-test (p<0.05, n=6 for Control, n=8 for 
Sox9 KO). 
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Figure 7:  Confocal photomicrographs depicting BDA-labeled fibers extending to  
SMI-32 positive cells at the denervated (ipsilesional) parvocellular red nucleus.  
(A,B) Two photomicrographs of representative ipsilesional red nucleus SMI-32 positive 
cells from Sox9-ablated mice 6 weeks after MCAO.  BDA fibers shown in red are from 
neurons originating in the contralateral motor cortex.  Scale bar in A-B = 5 µm.    
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3.2.2 Sox9 ablation led to increased structural plasticity in the 
 contralesional corticospinal tract after MCAO 
 In the corticospinal tract (CST), long axons of the cortical pyramidal neurons 
decussate almost completely at the pyramidal decussation within the brainstem, and over 
90% of  fibers project via the dorsal funiculus, to the contralateral half of the spinal cord 
(Rouiller, Liang et al. 1991).  Figure 8A is a schematic highlighting the BDA injection 
into the right motor cortex, and the two corticospinal pathways of interest (with the black 
line representing normal innervation, and the dotted line extending to the denervated 
side).  Injection of BDA into the right (contralesional) side of the sensori-motor cortex 
resulted in clear positive staining in the dorsal funiculus of the left (ipsilesional) side of 
the spinal cord. BDA-staining at the level of cervical enlargement in the ipsilesional 
spinal cord (predominantly innervated side) showed no significant difference between 
Sox9 KO and control groups. 
 Our results revealed significantly higher numbers of BDA-labeled fibers present 
at the contralesional (deafferented) side of the cervical spinal cord in the Sox9 KO mice 
by a Student's t-test (p<0.05, average of 9.417 ± 2.173 fibers for controls and 19.06 ± 
2.325 fibers for Sox9 KO mice).  In order to control for labeling efficiency differences 
among animals, this number was normalized to the number of BDA-labeled fibers on the 
ipsilesional side.  The resulting percentages of BDA-labeled fibers present within the 
deafferented contralesional cervical spinal cord were also significantly higher in the Sox9 
KO mice compared to control animals (p<0.05).  These results suggest increased 
structural plasticity in the contralesional corticospinal tract after MCAO in Sox9 KO 
animals. 
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Figure 8:  Sox9 KO mice display increased contralesional corticospinal neuroplasticity 
after MCAO compared to control animals. 
(A) Biotinylated dextran amine (BDA) was injected into the contralesional motor cortex 
and BDA-labeled fibers were quantified at the level of the cervical spinal cord. 
(B-E)  Photomicrographs of representative cervical spinal cord sections from control and 
Sox9-ablated mice six weeks after MCAO, both contralateral and ipsilateral to the BDA 
injection.  Scale bar in B, D = 100µm.  Scale bar in C, E = 25µm   (F) Quantification of the 
number of BDA-stained fibers crossing the midline to the contralesional cervical spinal 
cord.  The Sox9-ablated mice exhibited significantly higher numbers of BDA-labeled fibers 
on the denervated side compared to control mice as demonstrated by a Student's t-test 
(p<0.05, n=6 for Control, n=8 for Sox9 KO).  (G) Percentages of BDA labeled fibers 
present within the denervated, contralesional side of cervical spinal cord (number of BDA-
labeled fibers extending to denervated side normalized to the number of BDA-labeled 
fibers on the ipsilesional side).  The Sox9-ablated mice exhibited significantly higher 
percentages of BDA-labeled fibers on the denervated side compared to control mice as 
demonstrated by a Student's t-test (p<0.05, n=6 for Control, n=8 for Sox9 KO). 
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3.3  Effects of Sox9 ablation on putative synaptic plasticity after MCAO   
 To determine if Sox9 ablation in mice had an effect on synaptic neuroplasticity 
after MCAO, immunohistochemistry was used to examine glutamatergic input markers  
at the deafferented red nucleus and ventral horn of the cervical spinal cord.  Vesicular 
glutamate transporter 1 (VGLUT1) is the major glutamate transporter of corticorubral 
cells, while VGLUT2 is the major glutamate transporter of cerebellar inputs (Allen Brain 
Atlas - VGlut1 in mouse brain; Allen Brain Atlas - VGlut2 in mouse brain; Varoqui, 
Schafer et al. 2002; Fink, Englund et al. 2006).   Thus, it was of interest to see if levels of 
these important glutamatergic markers differed between genotypes, and if they correlated 
with the structural neuroplasticity data. VGLUT1 and/or VGLUT2 levels within the 
denervated red nucleus and cervical spinal cord were examined and counted six weeks 
after sham surgeries, as well as 48 hours and six weeks after the MCAO injury in both 
groups of animals. VGLUT levels were assessed to determine if Sox9 ablation led to 
increased levels of glutamatergic synaptic markers (and theoretically, increased 
innervation) within deafferented areas.  
 
3.3.1 Sox9 ablation led to increased levels of VGLUT1 input markers at 
 the deafferented red nucleus six weeks after MCAO 
 Results of a One-way ANOVA followed by a Newman-Keuls post-hoc test 
(Figure 9) revealed that 48 hours after MCAO, both control and Sox9 KO animals 
experienced a significant loss in VGLUT1 immunoreactivity at the deafferented, 
ipsilesional parvocellular red nucleus compared to sham animals (symbolized by 
statistically difference groups "a" and "b" on in Figure 9).  Sham animals were included 
to represent normal VGLUT1 levels.  However, six weeks after MCAO, Sox9-ablated 
animals displayed increased VGLUT1 immunoreactivity levels (statistically the same 
level as the Sham animals exhibited, denoted by the label "a" in the figure).  The control 
mice also experienced a significant increase in VGLUT1 levels at the ipsilesional red 
nucleus from 48 hours to six weeks-post MCAO (label "c" in Figure 9), but this was 
significantly lower than that measured in the sham animals and the six weeks post-
MCAO Sox9 KO mice.  
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Figure 9:  Sox9 KO mice display increased levels of VGLUT1 at the ipsilesional red 
nucleus six weeks post-MCAO compared to control animals, after a significant decrease in 
both groups 48 hours-post MCAO compared to shams. 
Representative photomicrographs of parvocellular red nucleus sections ipsilateral to 
MCAO from control and Sox9-ablated mice six weeks after a sham surgery (A, B), 48 
hours after MCAO (C, D), and six weeks after MCAO (E, F).  Vesicular glutamate 
transporter 1 (VGLUT1) in red represents glutamatergic input mainly from the motor 
cortex. SMI-32 in green represents rubrospinal neurons. Bar in A-F = 20 µm.   
(G) Quantified volume of VGLUT1 immunoreactivity per volume of red nucleus section 
for each animal type, and time point. There was a significant decrease in VGLUT1 
immunoreactivity between Sham animals and 48 hours post-MCAO animals for both 
groups. However, Sox9-ablated animals displayed increased VGLUT1 immunoreactivity 
levels six weeks after MCAO (attain same level as the Sham animals exhibit), whereas the 
control mice did not increase back to this normal level.  The different letters a, b, and c 
represent significantly different groups by One-way ANOVA, followed by a Newman-
Keuls post-hoc test (p<0.05, n=3 for Sham-Control and 48 hours-Sox9 KO, n=4 for Sham-
Sox9 KO,  n=5 for 48 hours-Sox9 KO and 6 weeks-Control, n=6 for 6 weeks-Sox9 KO). 
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3.3.2 Sox9 ablation did not lead to increased levels of VGLUT2 input 
 markers at the deafferented red nucleus six weeks after MCAO 
 Results of a One-way ANOVA followed by a Newman Keuls post-hoc test 
(Figure 10) revealed that there were no significant differences between control and Sox9 
KO animals at any individual time point.  Sham animals were included to represent 
normal VGLUT2 levels.  However, 48 hours after MCAO, control animals experienced a 
significant loss in VGLUT2 immunoreactivity at the deafferented, ipsilesional red 
nucleus compared to sham animals.  Both Sox9 KO and control animals exhibited 
significantly increased levels of VGLUT2 from 48 hours post-MCAO to six weeks after 
injury (p<0.05), but were statistically equivalent at the six weeks post-MCAO time point. 
 
3.3.3 Sox9 ablation did not significantly change levels of VGLUT1 input 
 markers at the deafferented cervical spinal cord ventral horn six 
 weeks after MCAO 
 Results of a One-way ANOVA revealed that VGLUT1 levels at the deafferented, 
contralesional cervical spinal cord ventral horn did not differ significantly between sham 
or six weeks post-MCAO animals in Sox9 KO or control groups (Figure 11, p>0.05). 
 
 
 
 
 
 
 
 
59 
 
 
 
 
Figure 10:  Sox9 KO mice exhibit no significant loss of VGLUT2 levels at the ipsilesional 
red nucleus 48 hours post-MCAO compared to sham animals, and both Sox9 knockout and 
control animals experience significantly increased levels of VGLUT2 by six weeks 
afterwards.  
Representative photomicrographs of ipsilesional parvocellular red nucleus sections from 
control and Sox9-ablated mice six weeks after a sham surgery (A, B), 48 hours after 
MCAO (C, D), and six weeks after MCAO (E, F).  Vesicular glutamate transporter 2 
(VGLUT2) in red represents glutamatergic input from other CNS areas (cerebellar and 
thalamic). SMI-32 in green represents rubrospinal neurons. Bar in A-F = 20 µm.  
(G) Quantified VGLUT2 volume of immunoreactivity per volume of red nucleus section 
for each animal type, and time point.  There were no significant differences in VGLUT2 
immunoreactivity levels between control and Sox9 KO animals at any individual time 
point. There were also no significant differences between Sham and six weeks-post MCAO 
groups (for control and Sox9 KO animals); However, at 48 hours post-MCAO, control 
animals displayed a significant decrease in VGLUT2 immunoreactivity  at the level of the 
deafferented parvocellular red nucleus compared to both types of Sham animals, whereas 
the Sox9 KO animals at 48 hours post-MCAO did not.  At six weeks post-MCAO, both 
control and Sox9 KO animals displayed significantly increased VGLUT2 levels 
(statistically equal to Sham, showing normal levels) compared to their counterparts at 48 
hours-post MCAO.  The * symbol represents a significant difference between two groups 
by One-Way ANOVA, followed by a Newman-Keuls post-hoc test (p<0.05, n=3 for Sham-
Control, Sham-Sox9 KO, and 48 hours-Sox9 KO,  n=5 for 48 hours-Control and 6 weeks-
Control, n=6 for 6 weeks-Sox9 KO). 
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Figure 11:  VGLUT1 levels at the contralesional cervical spinal cord ventral horn do not 
differ significantly between sham or six weeks post-MCAO animals in either Sox9 KO or 
control groups. 
Representative photomicrographs of contralesional cervical spinal cord ventral horn 
sections from control and Sox9-ablated mice six weeks after a sham surgery  (A, B), and 
six weeks after MCAO (C, D).  Vesicular glutamate transporter 1 (VGLUT1) in red 
represents glutamatergic input mainly from the motor cortex. NeuN in green is a marker for 
nuclei of neurons; large motor neurons of the ventral horn are evident. Bar in A-D = 
100µm.  (E) Quantified VGLUT1 area of immunoreactivity per area of cervical spinal cord 
ventral horn section for each animal type, and time point.  There were no significant 
differences in VGLUT1 immunoreactivity levels between the different groups of animals 
as determined by a One-Way ANOVA (p>0.05, n=4 for Sham-Control and Sham-Sox9 
KO,  n=5 for 6 weeks-Sox9 KO, n=6 for 6 weeks-Control). 
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Chapter 4: 
 
Discussion 
 This research project aimed to enhance understanding of the role of the 
transcription factor SOX9 in stroke pathology and recovery.  Having previously 
identified SOX9 as responsible for upregulating the expression of axonal growth- 
inhibiting CSPGs in the injured CNS, we hypothesized that decreasing levels of SOX9 
would result in increased neuroplasticity, and in turn, improved functional recovery after 
stroke in mice.  To achieve this, we used a conditional knockout mouse model in which 
exons 2 and 3 of the Sox9 were removed with a Cre-loxP system, inducible by tamoxifen 
administration.   It is pertinent to note that in this model, Sox9 would theoretically be 
knocked out in all cell types.  
 
4.1  The influence of SOX9 on functional recovery after stroke 
 The first objective of my thesis was to determine whether or not conditionally 
knocking out Sox9 would alter functional recovery after stroke in mice. Three separate 
behavioural tests were implemented to assess neurological and motor function after 
MCAO.  Used to detect sensori-motor and postural asymmetries, the corner test results 
displayed perhaps the most significant example of improved sensori-motor recovery after 
stroke in the Sox9-ablated mice compared to control animals.   Sox9 KO mice were 
exhibiting pre-injury behaviour of no side preference for turning by two weeks after 
MCAO, whereas the control animals displayed significantly slower progress and lower 
levels of sensori-motor recovery over the four post-injury weeks.  The corner test is 
known to be one of most reliable tests for detecting long-term sensori-motor dysfunction 
in rodents after injury (Zhang, Schallert et al. 2002). Thus, it was encouraging that the 
results to this sensitive test revealed the most prominent significant differences between 
Sox9 KO and control animals out of all behavioural tests (significant effects of genotype 
and time, as well as genotype-time interactions on all post-surgical weeks).  
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 Other important markers of functional recovery after stroke include use and 
strength of the paretic limb.  The cylinder test results demonstrated overall improved 
functional recovery after MCAO in Sox9 KO mice compared to control animals, with 
significant effects of both genotype and time in forelimb use asymmetry over the four 
week post-surgical testing period,  The results also suggested that Sox9 KO mice used the 
unaffected and paretic forelimbs equally to explore the cylinder wall by two weeks after 
MCAO (asymmetry score of 0.008 ± 0.12).  The grip strength test highlighted 
significantly improved recovery in strength of the paretic limb in the Sox9-ablated 
animals compared to controls animals, with a significant effect of both genotype and 
time.  The data suggested that Sox9 KO animals achieved full recovery of grip strength 
(96.8 ± 3.3%) by the end of the testing period.     
  The general trend seen with the behavioural test data confirmed our hypothesis 
that the Sox9 KO would display improved functional recovery after MCAO compared to 
control animals.  It is of interest to note that mice, in general, experience endogenous 
recovery to a remarkable degree after stroke (in comparison to humans).  It is a unique 
characteristic of the lissencephalic rodent brain that allows mice to survive larger strokes 
in considerable numbers (Carmichael 2005).  Along with higher survival rates, the time-
course of post-stroke recovery is often much shorter in rodents than in humans (Murphy 
and Corbett 2009). This implies that decreasing levels of SOX9 within the mice improved 
and augmented the already relatively high levels of endogenous sensori-motor recovery.  
It is possible that decreasing levels of SOX9 affects a few different processes that, in 
combination, produce significant functional improvements seen in the ubiquitous Sox9 
knockout mice.  As discussed in the introduction, ample evidence in the literature (and 
work completed by our research group) led to our hypothesis that lower SOX9 levels, and 
in turn lower CSPG levels, could result in increased neuroplasticity.  Therefore, after 
behavioural testing, examining neuroplasticity in these animals was our primary focus.  
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4.2   The influence of SOX9 on neuroplasticity after stroke 
 The two main mechanisms for neuroplastic change and reorganization after stroke 
are thought to be the formation of new neuronal circuitry, and the 
unmasking/strengthening of existing pathways (Soleman, Yip et al. 2012).  Thus the 
second objective of my thesis was to evaluate structural and synaptic neuroplasticity after 
MCAO in mice, and compare between Sox9-ablated mice and controls.  There are many 
ways to assess neuroplasticity; however, the two methods used in this work were tract-
tracing of the contralesional corticorubral and corticospinal pathways, as well as 
immunohistological quantification of glutamatergic input synaptic markers at 
deafferented CNS areas relevant to motor function. 
 
4.2.1 Examination of structural neuroplasticity after stroke 
 Tract-tracing findings supported our hypothesis that the Sox9-ablated mice would 
exhibit increased structural neuroplasticity after MCAO compared to controls. I 
examined labeled axons of neurons originating in the uninjured side of the sensori-motor 
cortex, and focused on two areas of descending projections that are very relevant to 
motor function: the red nucleus in the midbrain and cervical enlargement of the spinal 
cord.  The literature shows that in control animals, these predominantly unilateral 
connections become increasingly bilateral after stroke, as contralesional corticofugal 
axons sprout to innervate deafferented areas (Lee, Kim et al. 2004; Zai, Ferrari et al. 
2009).   
  In the present study, significantly higher numbers (and overall percentages, when 
controlling for labeling efficiency) of BDA-labeled fibers were found within the 
deafferented red nuclei and cervical spinal cords of the Sox9 KO animals compared to 
controls animals six weeks after MCAO.  This indicates that conditionally knocking out 
Sox9 significantly enhanced the endogenous structural plasticity of the contralesional 
corticorubral and corticospinal tracts seen in control animals.  This is likely due to a) 
increased sprouting of contralaterally projecting corticorubral axons that normally 
contribute only minimally (<1%) to corticorubral inputs (Z'Graggen, Metz et al. 1998; 
66 
 
Reitmeir, Kilic et al. 2011; Herz, Reitmeir et al. 2012), and b) increased sprouting of 
ispilaterally projecting corticospinal axons that normally contribute only minimally (2-
4%) to corticospinal inputs (Rouiller, Liang et al. 1991).. The growth of corticofugal 
fibers across the midline to reach deafferented areas may still be a formal possibility; 
however, sprouting of uninjured axons that were already within the deafferented areas 
may be more likely to contribute to the improved function recovery of the Sox9 KO mice, 
since axon growth is a relatively slow process (Cho, Yang et al. 2005).    
 Whether it was an increase in collateral connections, or an elaboration of 
unilateral connections to the denervated areas that were present before injury, increased 
contralesional corticofugal structural neuroplasticity was observed in the Sox9 KO 
animals compared to controls. We hypothesize that this was due to the consequently 
lower levels of CSPGs (both in the diffuse extracellular matrix and dense peri-neuronal 
nets) in the knockout animals, which would have theoretically created a CNS 
environment more permissive to axon sprouting.  The increased structural plasticity of 
uninjured corticofugal fibers may have contributed to the improved functional recovery 
observed in the Sox9 KO mice.  Further studies might include electrophysiological 
experiments to determine whether or not this increased fiber growth into deafferented 
area does, in fact, translate into increased functionality. 
 
4.2.2 Examination of synaptic neuroplasticity after stroke: glutamatergic 
 input markers at the denervated red nucleus 
 If the improved functional recovery observed in the Sox9 KO mice is due the 
increased reactive sprouting of corticofugal projections (demonstrated by the BDA-
labeling) , then one would predict that the Sox9 KO mice would also demonstrate 
increased expression levels of synaptic proteins in the deafferented red nucleus and 
cervical spinal cord compared to controls.  Thus, we examined the expression levels of 
presynaptic markers in the ipsilesional red nucleus and contralesional cervical spinal 
cord.  The literature suggests that VGLUT expression is used endogenously to directly 
regulate the extent of glutamate release, which presents a presynaptic mechanism to 
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control excitatory transmission for synaptic refinement and plasticity (Wilson, Kang et al. 
2005).  Therefore, a change in presynaptic VGLUT levels suggests a change in excitatory 
innervation.  The quantification of synaptic markers has been used in other central 
nervous system injury studies to examine probable changes in innervation at deafferented 
areas (e.g. the spinal cord) (Apostolova, Irintchev et al. 2006; Zhao, Zhao et al. 2013).  
Our tract tracing findings displayed an increase in fibers projecting from the uninjured 
sensori-motor cortex to the deafferented parvocellular red nucleus in the Sox9 KO 
animals, so it was of interest to see if this corresponded with an increase in VGLUT 
expression.  
 As discussed in the introduction, the corticorubral tract is composed of 
glutamatergic neurons, with VGLUT1 as the predominantly expressed vesicular 
glutamate transporter (Allen Brain Atlas -VGlut1 in mouse brainBromberg, Penney et al. 
1981).  The immunohistological analysis revealed that both Sox9 KO and control mice 
experienced loss of VGLUT1 levels at the deafferented parvocellular red nucleus by 48 
hours post-MCAO.  The small, however significant, increase in VGLUT1 levels 
exhibited by the control animals at six weeks post-MCAO testifies to the neuroplasticity 
that normally occurs post-stroke.   The Sox9 KO mice exhibited full restoration of 
VGLUT1 levels by six weeks post-MCAO (statistically equivalent to sham levels), which 
suggests a heightened level of neuroplasticity in these mice compared to controls. The 
significantly higher VGLUT1 levels at the deafferented red nucleus in the knockout 
animals corresponded with an increased presence of fibers projecting from the 
contralesional sensori-motor cortex.  Again, we hypothesize that this occurred due to 
lower levels of CSPGs (both in diffuse extracellular matrix and dense peri-neuronal nets), 
which created a CNS environment more permissive to neuroplasticity and synapse 
formation.  
 
 Further experiments may include co-staining for BDA and VGLUT1 at the 
deafferented parvocellular red nucleus.  Co-localization would suggest that the 
contralesional corticorubral fibers expressed the presynaptic glutamatergic transporter 
proteins necessary to make functional connections with deafferented neurons.  Another 
useful experiment to further provide evidence of putative functional synapses would 
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involve co-staining for presynaptic VGLUT1 proteins and corresponding post-synaptic 
density proteins (PSD).  PSD-95 is the most ubiquitous and best characterized of the 
glutamatergic PSD proteins, and is thought to be fundamentally important in anchoring 
AMPA (α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors at the post-
synaptic membrane (Bruneau, Esteban et al. 2009).  Since proper post-synaptic protein 
expression is also essential to synapse functionality, co-localization of VGLUT1 and 
PSD-95 at cell membranes of interest would further suggest potential synapse 
functionality. Again, electrophysiological studies would be ideal to reinforce this 
hypothesis, and confirm the existence of functional connections.  
 VGLUT2 levels at the deafferented red nucleus tell a somewhat different story.  
Another major glutamatergic input to the red nucleus extends from the deep cerebellar 
nuclei of the cerebellum; these projections are predominantly VGLUT2-positive (Allen 
Brain Atlas - VGlut2 in mouse brain; Fink, Englund et al. 2006).  Efferent projections to 
the parvocellular red nucleus also extend from the posterior thalamic nuclei.  Since 
VGLUT2 has been established as the most abundant VGLUT isoform of thalamic nuclei, 
this is likely a source of VGLUT2 innervation as well (Moechars, Weston et al. 2006; 
Barroso-Chinea, Castle et al. 2007).  Together, cerebellar and thalamic glutamatergic 
innveration at the red nucleus play a role in movement coordination and proper 
integration of sensori-motor information (Roger and Cadusseau 1987; Siegel 2010) 
 Immunohistological analysis revealed that only control animals experienced a 
significant decrease in VGLUT2 levels at the deafferented red nucleus by 48 hours after 
stroke.  Since the red nucleus and cerebellum are both in areas of the brain that are not 
directly damaged by MCAO, it is unlikely that this loss of VGLUT2 levels was due to 
lost cerebellorubral connections. The thalamus does not receive direct blood supply from 
the MCA either; however, it is supplied by branches of the internal carotid artery, which 
is a vessel manipulated during the MCAO procedure.  This, in combination with its 
relative proximity to the infarcted area, may have put the thalamus at risk for damage 
from ischemia or secondary processes (Popp, Jaenisch et al. 2009).  As such, there is a 
chance that some degree of ischemic damage occurred, leading to a slight decrease in 
thalamorubral VGLUT2-positive input to the red nucleus.  In the Sox9 KO animals, there 
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was no significant decrease in VGLUT2 input at 48 hours post-MCAO, which may have 
been due to some sort of neuroprotective effect caused by Sox9 ablation.  However, 
similar evidence for neuroprotection was not observed in the VGLUT1 analyses.  In any 
case, it would be advantageous to complete future experiments to examine the possibility 
of neuroprotection (such as retrograde tract tracing from deafferented areas) and compare 
between genotypes.   
 Finally, both Sox9 KO and control animals experienced a significant increase in 
VGLUT2 levels at the deafferented parvocellular red nucleus from 48 hours after injury 
to reach normal levels by six weeks post-MCAO.  In the control animals, this may have 
once again been due to endogenous levels of neuroplasticity.  Since the control animals 
did not attain normal levels of VGLUT1 expression at the deafferented red nucleus by six 
weeks after MCAO, an increase in excitatory innervation from other areas may have been 
a more needed and encouraged compensatory response.   The lack of a significant 
difference between control and Sox9 KO animals by six weeks after MCAO may indicate 
that VGLUT2-positive innervation (most likely of thalamic and cerebellar origin) at the 
deafferented red nucleus did not play a major role in the improved functional recovery 
seen in the knockout animals.  
 
4.2.3 Examination of synaptic neuroplasticity after stroke: glutamatergic 
 input markers at the denervated cervical spinal cord ventral horn 
 As discussed in the introduction, the corticospinal tract is composed of 
glutamatergic neurons, with VGLUT1 as the predominant vesicular glutamate transporter 
expressed (Allen Brain Atlas -VGlut1 in mouse brainBromberg, Penney et al. 1981; 
Varoqui, Schafer et al. 2002).  The immunohistological analysis of VGLUT1 levels at the 
deafferented cervical spinal cord ventral horn revealed that there were no significant 
differences between control or Sox9 KO animals six weeks post-MCAO.  VGLUT1 
levels at six weeks-post MCAO in both groups of mice were also were statistically 
equivalent to those exhibited by sham animals.   It is interesting to note that, unlike the 
VGLUT1 immunohistochemistry analysis at the red nucleus, this data does not correlate 
with the tract tracing findings; the BDA experiments showed that more fibers from the 
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contralesional cortex were present within the deafferented cervical spinal cord in the Sox9 
KO animals six weeks after MCAO compared to controls.   
 This may have resulted for a number of reasons.  It is possible that other 
glutamatergic inputs to the deafferented cervical spinal cord ventral horn played a role in 
the improved functional recovery seen in the knockout animals.  Since putative 
contralesional corticorubral VGLUT1 innveration was significantly higher in the 
deafferented red nucleus of the Sox9 KO mice six weeks after MCAO, this may have 
translated into improved function due to enhanced rubrospinal activity.  The rubrospinal 
tract is VGLUT2 positive, which was not analyzed at the deafferented cervical spinal 
cord in the present study (Liang, Paxinos et al. 2012Liang, Paxinos et al. 2012).   It is 
also necessary to note that evidence of structural plasticity with tract tracing does not 
necessarily mean that functional synapses were formed; VGLUT proteins may not have 
been present in the axon terminals of the BDA-labeled fibers to create functional 
synapses.  Therefore, one explanation for these data is that increased functional 
connectivity of the contralesional corticospinal tract to the deafferented cervical spinal 
cord may not have occurred to play a role in the improved functional recovery exhibited 
by the knockout mice. 
 
 On the other hand, Since VGLUT expression at the cervical spinal cord ventral 
horn was measured over a much larger area than it was at the red nucleus, a difference 
between genotypes may not have been large enough to be detected and to achieve 
statistical significance.  Perhaps a difference in VGLUT1 staining due to 2.957 ± 0.5663 
percent of overall labeled contralesional fibers present at the deafferented cervical spinal 
cord in the control mice versus 5.856 ± 0.7764 percent in the Sox9 KO mice was not 
substantial enough to display a significant difference between genotypes (when 
immunoreactivity of all sources of VGLUT1 on all neurons of the cervical spinal cord 
ventral horn was measured).  Arguably, a more accurate way to examine possible 
synapses of interest is to count puncta of synaptic markers around specific cells of 
interest (e.g. motor neurons in the spinal cord and rubrospinal neurons in the red 
nucleus).  Interestingly enough, recent work done by our research group has shown that 
numbers of VGLUT1 puncta surrounding motor neurons of the deafferented cervical 
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spinal cord ventral horn are significantly higher in the Sox9 KO animals compared to 
those in the controls after stroke.  Thus, it is possible that this difference was simply 
diluted by the large area that VGLUT1 immunoreactivity was measured over the 
deafferented cervical spinal cord ventral horn in the present study.  Immunohistological 
co-localization of VGLUT1 and BDA would be another beneficial follow-up experiment 
to further establish evidence of putative synapses of the contralesional corticospinal tract.  
VGLUT1 and PSD-95 co-localization would also give insight as to whether or not both 
pre-and post-synaptic proteins were aligning for proper synapse functionality.  Again, 
electrophysiological studies would be ideal to elucidate these findings. 
 
4.3 Conclusions 
 Overall,  Sox9 KO animals exhibited improved functional recovery after a 30 
minute MCAO compared to control animals.  We hypothesized that this may occur due to 
increased neuroplasticity in the Sox9 KO animals, since previous studies by our research 
group showed that Sox9 ablation caused a decrease in the expression of axon growth-
inhibiting CSPGs in the CNS.  Tract-tracing findings supported our hypothesis: the Sox9-
ablated mice exhibited increased contralesional corticofugal structural neuroplasticity 
compared to control mice when BDA-labeled fibers were analyzed at the denervated red 
nucleus and cervical spinal cord after MCAO. 
 Putative synaptic neuroplasticity was examined with markers for presynaptic 
glutamatergic input within the deafferented areas. Sox9 KO animals exhibited 
significantly higher levels of VGLUT1 at the deafferented red nucleus by six weeks after 
MCAO compared to control mice.  Since VGLUT1 is the main VGLUT isoform of the 
corticorubral tract, this data correlated nicely with the tract tracing findings to support the 
hypothesis.  Higher levels of synaptic neuroplasticity in the Sox9 KO animals for the 
thalamorubral, cerebellorubral, or corticospinal tracts (which are also important for motor 
function) were not evident with the presented immunohistological analyses.  Further 
studies (e.g. counting puncta or co-localizing synaptic markers on cells of interest, as well 
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as electrophysiological experiments) would be very beneficial to explore neuroplasticity 
further.   
 The improved functional recovery observed in the Sox9 KO mice is certainly 
interesting.  Evidence of increased contralesional corticorubral and corticospinal 
plasticity is encouraging, and correlates nicely with the previously observed lower levels 
of CSPGs and PNNs in the Sox9 KO mice central nervous system.  Further unraveling the 
exact mechanisms that elicited the improved functional recovery observed in Sox9-
ablated mice after stroke could lead to the development of novel stroke treatments for 
humans. 
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